Document:

EX-10.1

 Exhibit 10.1 

$400,000,000 
 U.S. CONCRETE, INC.

 6.375% Senior Notes due 2024 

Purchase Agreement 

    May 23, 2016 

J.P. Morgan Securities LLC 
   As Representative of the

   several Initial Purchasers listed 

  in Schedule 1 hereto 
 c/o J.P. Morgan Securities LLC

 383 Madison Avenue 
 New York, New York 10179 

Ladies and Gentlemen: 
 U.S. Concrete, Inc., a
Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the
“Representative”), $400,000,000 principal amount of its 6.375% Senior Notes due 2024 (the “Securities”). The Securities will be issued pursuant to an Indenture to be dated as of June 7, 2016 (the
“Indenture”) among the Company, the guarantors listed in Schedule 2 hereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), and will be guaranteed on a
senior unsecured basis by each of the Guarantors (the “Guarantees”). 
 The Securities will be sold to the Initial
Purchasers without being registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon an exemption therefrom. The Company and the Guarantors have prepared a preliminary offering memorandum dated
May 23, 2016 (the “Preliminary Offering Memorandum”) and will prepare an offering memorandum dated the date hereof (the “Offering Memorandum”) setting forth information concerning the Company, the Guarantors and the
Securities. Copies of the Preliminary Offering Memorandum have been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this purchase agreement (the
“Agreement”). The Company hereby confirms that it has authorized the use of the Preliminary Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection with the offering and
resale of the Securities by the Initial Purchasers in the manner contemplated by this Agreement. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Preliminary Offering Memorandum. References herein to
the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum shall be deemed to refer to and include any document incorporated by reference therein and any reference to “amend,” “amendment” or
“supplement” with respect to the Preliminary Offering Memorandum or the Offering Memorandum shall be deemed to refer to and include any documents filed after such date and incorporated by reference therein. 

  

 At or prior to the time when sales of the Securities were first made (the “Time of
Sale”), the Company had prepared the following information (collectively, the “Time of Sale Information”): the Preliminary Offering Memorandum, as supplemented and amended by the written communications listed on Annex A
hereto. 
 The Company intends to use the proceeds of the offering of the Securities to (i) repay all of the outstanding borrowings under
its asset-based senior secured revolving credit facility, (ii) to redeem or otherwise retire all of its outstanding 8.50% Senior Secured Notes due 2018 (the “Existing Notes”) (such uses, the “Transactions”) and
(iii) for general corporate purposes as described under “Use of Proceeds” in the Time of Sale Information. The Company has issued an irrevocable conditional notice of optional redemption dated May 17, 2016 with respect to the Existing
Notes (the “Existing Notes Redemption Notice”), which provides, subject to the condition precedent set forth therein, for the redemption of the Existing Notes on June 16, 2016 (the “Existing Notes Redemption Date”).
The Company (i) shall use a portion of the proceeds of the offering of the Securities to deposit an amount equal to the sum of (x) the product of the redemption price (expressed as a percentage of the aggregate principal amount) for the Existing
Notes and the aggregate principal amount thereof and (y) all accrued interest on the Existing Notes to the redemption date (the “Existing Notes Redemption Deposit”) on or promptly after the Closing Date with the trustee under the
indenture governing the Existing Notes, and (ii) intends to satisfy the other conditions precedent to the satisfaction and discharge of the indenture that governs the Existing Notes. 

Holders of the Securities (including the Initial Purchasers and their direct and indirect transferees) will be entitled to the benefits of a
Registration Rights Agreement, to be dated as of the Closing Date and substantially in the form attached hereto as Exhibit A (the “Registration Rights Agreement”), pursuant to which the Company and the Guarantors will agree to file
one or more registration statements with the Securities and Exchange Commission (the “Commission”) providing for the registration under the Securities Act of the Securities or the Exchange Securities referred to (and as defined) in
the Registration Rights Agreement and the related Guarantees. 
 The Company and the Guarantors hereby confirm their agreement with the
several Initial Purchasers concerning the purchase and resale of the Securities, as follows: 
 1. Purchase and Resale of the
Securities. 
 (a) The Company agrees to issue and sell the Securities to the several Initial Purchasers as provided in this Agreement,
and each Initial Purchaser, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company the respective principal
amount of Securities set forth opposite such Initial Purchaser’s name in Schedule 1 hereto at a price equal to 98.5% of the principal amount thereof plus accrued interest, if any, from June 7, 2016 to the Closing Date. The Company will not be
obligated to deliver any of the Securities except upon payment for all the Securities to be purchased as provided herein. 

  
 2 

 (b) The Company understands that the Initial Purchasers intend to offer the Securities for resale
on the terms set forth in the Time of Sale Information. Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 

(i) it is a qualified institutional buyer within the meaning of Rule 144A under the Securities Act (a “QIB”)
and an accredited investor within the meaning of Rule 501(a) of Regulation D under the Securities Act (“Regulation D”); 

(ii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities by
means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act; and 

(iii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities as
part of their initial offering except: 
 (A) to persons whom it reasonably believes to be QIBs in transactions pursuant to Rule 144A under
the Securities Act (“Rule 144A”) and in connection with each such sale, it has taken or will take reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on Rule 144A; or

 (B) in accordance with the restrictions set forth in Annex C hereto. 

(c) Each Initial Purchaser acknowledges and agrees that the Company and, for purposes of the “no registration” opinions to be
delivered to the Initial Purchasers pursuant to Sections 6(f) and 6(h) hereof, counsel for the Company and counsel for the Initial Purchasers, respectively, may rely upon the accuracy of the representations and warranties of the Initial Purchasers
and compliance by the Initial Purchasers with their agreements, in each case, contained in paragraph (b) above (including Annex C hereto), and each Initial Purchaser hereby consents to such reliance. 

(d) The Company acknowledges and agrees that the Initial Purchasers may offer and sell Securities to or through any affiliate of an Initial
Purchaser and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser. 
 (e) The Company
and the Guarantors acknowledge and agree that each Initial Purchaser is acting solely in the capacity of an arm’s length contractual counterparty to the Company and the Guarantors with respect to the offering of Securities contemplated hereby
(including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company, the Guarantors or any 

  
 3 

 
other person. Additionally, neither the Representative nor any other Initial Purchaser is advising the Company, the Guarantors or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company and the Guarantors shall consult with their own advisors concerning such matters and shall be responsible for making their own independent investigation and appraisal of the
transactions contemplated hereby, and neither the Representative nor any other Initial Purchaser shall have any responsibility or liability to the Company or the Guarantors with respect thereto. Any review by the Representative or any Initial
Purchaser of the Company, the Guarantors, and the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representative or such Initial Purchaser, as the case may be, and shall
not be on behalf of the Company, the Guarantors or any other person. 
 2. Payment and Delivery. 

(a) Payment for and delivery of the Securities will be made at the offices of Cravath, Swaine & Moore LLP, 825 Eighth Avenue, New York,
New York 10019 at 10:00 A.M., New York City time, on June 7, 2016, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing. The
time and date of such payment and delivery is referred to herein as the “Closing Date”. 
 (b) Payment for the Securities
shall be made by wire transfer in immediately available funds to the account(s) specified by the Company to the Representative against delivery to the nominee of The Depository Trust Company (“DTC”), for the account of the Initial
Purchasers, of one or more global notes representing the Securities (collectively, the “Global Note”), with any transfer taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Note will be
made available for inspection by the Representative not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date. 

3. Representations and Warranties of the Company and the Guarantors. The Company and the Guarantors jointly and severally
represent and warrant to each Initial Purchaser that: 
 (a) Preliminary Offering Memorandum, Time of Sale Information and Offering
Memorandum. The Preliminary Offering Memorandum, as of its date, did not, the Time of Sale Information, at the Time of Sale, did not, and at the Closing Date, will not, and the Offering Memorandum, in the form first used by the Initial
Purchasers to confirm sales of the Securities and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided that the Company and the Guarantors make no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any
Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative expressly for use in the Preliminary Offering Memorandum, the Time of Sale Information or the Offering Memorandum, it being understood and
agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in Section 7(b) hereof. 

  
 4 

 (b) Additional Written Communications. The Company and the Guarantors (including their
agents and representatives, other than the Initial Purchasers in their capacity as such) have not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any written communication
that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company and the Guarantors or their agents and representatives (other than a communication referred to in clauses (i) and (ii)
below), an “Issuer Written Communication”) other than (i) the Preliminary Offering Memorandum, (ii) the Offering Memorandum, (iii) the documents listed on Annex A hereto, including a term sheet substantially in the form of Annex B
hereto, which constitute part of the Time of Sale Information, and (iv) any electronic road show or other written communications, in each case, used in accordance with Section 4(c). Each such Issuer Written Communication, when taken together with
the Time of Sale Information at the Time of Sale, did not, and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company and the Guarantors make no representation or warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance
upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative expressly for use in any Issuer Written Communication, it being understood and agreed
that the only such information furnished by any Initial Purchaser consists of the information described as such in Section 7(b) hereof. 

(c) Incorporated Documents. The documents incorporated by reference in each of the Time of Sale Information and the
Offering Memorandum, at the respective times they were or hereafter are filed with the Commission, complied or will comply as to form, as the case may be, in all material respects to the requirements of the Exchange Act and the rules and regulations
of the Commission thereunder, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading. 
 (d) Financial Statements. The financial statements and the related notes thereto
included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum present fairly in all material respects the financial position of the Company and its subsidiaries as of the dates indicated and the results of
their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with U.S. generally accepted accounting principles applied on a consistent basis throughout the periods
covered thereby; and the other financial information included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum has been derived from the accounting records of the Company and its subsidiaries and
presents fairly in all material respects the information shown thereby. The interactive data in eXtensbile Business Reporting Language included or incorporated by reference in each of the Preliminary Offering

  
 5 

 
Memorandum, the Time of Sale Information and the Offering Memorandum to the extent set forth in Rule 402(a)(2) of Regulation S-T fairly presents the information called for in all material
respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. 
 (e) No Material Adverse
Change. Since the date of the most recent financial statements of the Company included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum, except as otherwise disclosed in each of the Time of
Sale Information and the Offering Memorandum, (i) there has not been any material change in the capital stock or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment,
paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, rights, assets, management, financial position,
results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as
a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its
business that is material to the Company and its subsidiaries taken as a whole from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or any action, order or decree of any court or arbitrator or
governmental or regulatory authority. 
 (f) Organization and Good Standing. The Company and each of its subsidiaries have been
duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or
lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where
the failure to be so qualified, in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, rights, assets, management, financial position, results of
operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company and the Guarantors of their obligations under this Agreement, the Securities and the Guarantees (“Material Adverse
Effect”). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Schedule 3 to this Agreement. 

(g) Capitalization. The Company has the capitalization as set forth in each of the Time of Sale Information and the Offering Memorandum
under the heading “Capitalization”; and all the outstanding shares of capital stock or other equity interests of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are
owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party (collectively, “Liens”), except for Liens
pursuant to (i) the Second Amended and Restated Loan and Security Agreement, dated as 

  
 6 

 
of November 18, 2015, among the Company, certain of its subsidiaries party thereto, the lenders party thereto and Bank of America, N.A., as administrative agent (the “Credit
Agreement”) and (ii) the Existing Notes, which Liens, in the case of clause (ii), if the Company receives the proceeds of the offering of the Securities, will be released and terminated on the Existing Notes Redemption Date, or, if earlier,
upon the satisfaction and discharge of the indenture governing the Existing Notes. 
 (h) Due Authorization. The Company and each of
the Guarantors have the requisite corporate, limited liability company, or limited partnership, as applicable, right, power and authority to execute and deliver this Agreement, the Securities, the Indenture (including each Guarantee set forth
therein), the Exchange Securities (including the related Guarantees) and the Registration Rights Agreement, in each case, to the extent a party thereto (collectively, the “Transaction Documents”) and to perform their respective
obligations hereunder and thereunder; and all action required to be taken for the due and proper authorization, execution and delivery of each of the Transaction Documents and the consummation of the transactions contemplated thereby has been duly
and validly taken. 
 (i) The Indenture. The Indenture (including the Guarantees set forth therein) has been duly authorized by the
Company and each of the Guarantors and on the Closing Date will be duly executed and delivered by the Company and each of the Guarantors and, when duly executed and delivered in accordance with its terms by each of the parties thereto, will
constitute a valid and legally binding agreement of the Company and each of the Guarantors enforceable against the Company and each of the Guarantors in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent transfer or conveyance or other similar laws affecting the enforcement of creditors’ rights generally or by equitable principles relating to enforceability (collectively, the
“Enforceability Exceptions”); and on the Closing Date, the Indenture will conform in all material respects to the requirements of the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the
rules and regulations of the Commission applicable to an indenture that is qualified thereunder. 
 (j) The Securities and the
Guarantees. The Securities have been duly authorized by the Company and, when duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and
will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture; and the Guarantees
have been duly authorized by each of the Guarantors and, when the Securities have been duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be valid and legally binding obligations of
each of the Guarantors, enforceable against each of the Guarantors in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 

(k) The Exchange Securities. On the Closing Date, the Exchange Securities (including the related Guarantees) will have been duly
authorized by the Company and 

  
 7 

 
each of the Guarantors and, when duly executed, authenticated, issued and delivered in connection with the exchange offer as contemplated by the Registration Rights Agreement, will be duly and
validly issued and outstanding and will constitute valid and legally binding obligations of the Company, as issuer of such Exchange Securities, and each of the Guarantors, as guarantor of such Exchange Securities, enforceable against the Company and
each of the Guarantors in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 

(l) Purchase and Registration Rights Agreements. This Agreement has been duly authorized, executed and delivered by the Company and
each of the Guarantors; and the Registration Rights Agreement has been duly authorized by the Company and each of the Guarantors and on the Closing Date will be duly executed and delivered by the Company and each of the Guarantors and, when duly
executed and delivered in accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company and each of the Guarantors enforceable against the Company and each of the Guarantors in
accordance with its terms, subject to the Enforceability Exceptions, and except that rights to indemnity and contribution thereunder may be limited by applicable law and public policy. 

(m) Descriptions of the Transaction Documents. Each Transaction Document conforms in all material respects to the description
thereof contained in each of the Time of Sale Information and the Offering Memorandum. 
 (n) No Violation or Default. Neither
the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the
due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or
governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. 

(o) No Conflicts. The execution, delivery and performance by the Company and each of the Guarantors of each of the Transaction
Documents to which each is a party, the issuance and sale of the Securities and the issuance of the related Guarantees, the issuance of the Exchange Securities and the related Guarantees and the consummation of the transactions contemplated by the
Transaction Documents will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or
imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or
any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is 

  
 8 

 
subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of
any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, termination,
modification, acceleration, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. 

(p) No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or
arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company and each of the Guarantors of each of the Transaction Documents to which each is a party, the issuance and sale of the
Securities and issuance of the related Guarantees, the issuance of the Exchange Securities and the related Guarantees and the consummation of the transactions contemplated by the Transaction Documents, except for such consents, approvals,
authorizations, orders, registrations or qualifications as may be required (i) under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers and (ii) with respect to the Exchange
Securities (including the related Guarantees) and the Indenture, under the Securities Act, the Trust Indenture Act and applicable state securities laws as contemplated by the Registration Rights Agreement. 

(q) Legal Proceedings. Except as described in each of the Time of Sale Information and the Offering Memorandum, there are no
legal, governmental or regulatory investigations, actions, suits, or proceedings (“Actions”) pending to which the Company or any of its subsidiaries is a party or to which any property, right or asset of the Company or any of its
subsidiaries is subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; and no such Actions are, to the knowledge of the
Company and each of the Guarantors, threatened or contemplated by any governmental or regulatory authority or by others. 
 (r)
Independent Accountants. Grant Thornton LLP, who have certified certain financial statements of the Company and its subsidiaries, is an independent public accountant with respect to the Company and its subsidiaries within the applicable
rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. 

(s) Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple to, or have valid
rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case, free and clear of all Liens and defects and imperfections of title, except,
in the case of any real property subject to a mortgage that secures the Credit Agreement or the Existing Notes, Liens permitted by the Credit Agreement or the indenture for the Existing Notes, and in the case of personal property, Liens that (i) do
not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries, (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or (iii) secure the

  
 9 

 
Credit Agreement or the Existing Notes, which Liens with respect to the Existing Notes, will be released and terminated on the Existing Notes Redemption Date, or, if earlier, upon the
satisfaction and discharge of the indenture governing the Existing Notes. 
 (t) Intellectual Property. (i) The Company and its
subsidiaries own or have the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names, copyrights and copyrightable works (collectively,
“Intellectual Property”) material to the conduct of their respective businesses as currently conducted; (ii) to the knowledge of the Company and any Guarantor, the Company and its subsidiaries’ conduct of their respective
businesses does not infringe, misappropriate or otherwise violate any Intellectual Property of any person; (iii) the Company and its subsidiaries have not received any written notice of any claim of infringement relating to the Company or any of its
subsidiary’s use of any Intellectual Property; and (iv) to the knowledge of the Company and any Guarantor, the Intellectual Property of the Company and their subsidiaries is not being infringed, misappropriated or otherwise violated by any
person. 
 (u) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of
its subsidiaries, on the one hand, and the directors, officers, 5% or greater stockholders or other affiliates of the Company or any of its subsidiaries, on the other, that would be required by the Securities Act to be described in a registration
statement on Form S-1 to be filed with the Commission and that is not so described in or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum. 

(v) Investment Company Act. Neither the Company nor any of the Guarantors is, and after giving effect to the offering and sale of the
Securities and the application of the proceeds thereof as described in each of the Time of Sale Information and the Offering Memorandum, none of them will be, an “investment company” or an entity “controlled” by an
“investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”). 

(w) Taxes. The Company and its subsidiaries have paid all material U.S. federal, state, local and foreign taxes and filed all
material income tax returns required to be paid or filed through the date hereof (taking into account any applicable extensions); and except as otherwise disclosed in each of the Time of Sale Information and the Offering Memorandum, there is no
material income tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets, except for any taxes the amount or validity of which is
currently being contested in good faith or for which adequate reserves have been provided in accordance with U.S. generally accepted accounting principles. 

(x) Licenses and Permits. The Company and its subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the conduct of their respective businesses in the manner contemplated by the Time of Sale Information and the Offering Memorandum, except
where the failure to possess such certificates, 

  
 10 

 
authorizations or permits would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in each of the Time of Sale Information and the Offering Memorandum,
neither the Company nor any of its subsidiaries has received notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, individually or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, could be reasonably expected to have a Material Adverse Effect, and the Company does not reasonably expect any future inability to acquire such certificates, authorizations and permits as are necessary to
conduct its business in the manner contemplated by each of the Time of Sale Information and the Offering Memorandum, except as would not have a Material Adverse Effect. 

(y) No Labor Disputes. No labor disturbance by, or dispute with, employees of the Company or any of its subsidiaries exists or, to the
knowledge of the Company and each of the Guarantors, is contemplated or threatened, except as would not have a Material Adverse Effect. Neither the Company nor any Guarantor is aware of any existing or imminent labor disturbance by, or dispute with,
the employees of any of the Company’s or any of the Company’s subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has
received any written notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party, except as would not have a Material Adverse Effect. 

(z) Compliance with Environmental Laws. Except as described in each of the Time of Sale Information and the Offering Memorandum, (i)
the Company and its subsidiaries (x) are, and at all prior times (except for such matters that have been fully and finally resolved) were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations,
requirements, binding decisions and orders relating to hazardous or toxic substances or wastes, pollutants or contaminants, the protection of human health or safety, the environment and natural resources (collectively, “Environmental
Laws”), (y) have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, and (z) have not
received written notice of any actual or potential liability under or relating to any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or
contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its
subsidiaries, except in the case of each of (i) and (ii) above, for any such failure to comply, or failure to receive required permits, licenses, certificates, authorizations, or approvals, or cost or liability, as would not, individually or in the
aggregate, have a Material Adverse Effect; and (iii) (x) there are no proceedings that are pending, or that are known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is
also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) compliance of the Company and its subsidiaries with Environmental Laws, or liabilities or other
obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants could not reasonably be expected to have a material effect on 

  
 11 

 
the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z) none of the Company and its subsidiaries anticipates material capital expenditures relating
to compliance with any Environmental Laws. 
 (aa) Compliance with ERISA. (i) Each employee benefit plan, within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any organization which is a member of a controlled group
of corporations within the meaning of Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained in compliance with
its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has
occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed
(whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be,
in “at risk status” (within the meaning of Section 303(i) of ERISA) or “endangered status” or “critical status” (within the meaning of Section 305 of ERISA); (v) the fair market value of the assets of each Plan exceeds
the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to
occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification and (viii) neither the
Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary
course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of ERISA), except, in each case, with respect to the events or conditions set forth in (i) through (viii) hereof,
as would not, individually or in the aggregate, have a Material Adverse Effect, or as disclosed in the Time of Sale Information or the Offering Memorandum. 

(bb) Disclosure Controls. The Company and its subsidiaries maintain an effective system of “disclosure controls and
procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow
timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. 

(cc) Accounting Controls. The Company and its subsidiaries maintain systems of “internal control over financial reporting”
(as defined in Rule 13a-15(f) of the 

  
 12 

 
Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
The Company and its subsidiaries, on a consolidated basis, maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance
with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive
data in eXtensbile Business Reporting Language included or incorporated by reference in each of the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum to the extent set forth in Rule 402(a)(2) of Regulation S-T
is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as disclosed in each of the Time of Sale Information and the Offering Memorandum, there were no material weaknesses in the Company’s internal
controls as of December 31, 2015. 
 (dd) Insurance. The Company and its subsidiaries, on a consolidated basis, have
insurance covering such losses and risks and in such amounts as the Company reasonably believes are adequate for the conduct of their business. Neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such
insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. 

(ee) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor any director or officer of the Company or any of
its subsidiaries nor, to the knowledge of the Company and each of the Guarantors, any agent, affiliate, employee or other person, in each case, associated with or acting on behalf of the Company or any of its subsidiaries, has (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or unlawful
benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the
foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the
OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv)
made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other 

  
 13 

 
unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful payment or unlawful benefit. The Company and its subsidiaries have instituted,
maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. 

(ff) Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at
all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable anti-money laundering
statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental
agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company or any of the Guarantors, threatened. 
 (gg) No
Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, nor any director or officer of the Company or any of its subsidiaries, nor, to the knowledge of the Company or any of the Guarantors, any agent, affiliate,
employee or other person, in each case, acting on behalf of the Company or any of its subsidiaries, is currently the subject or, to the knowledge of the Company, the target of any sanctions administered or enforced by the U.S. government,
(including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a “specially designated
national” or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, the
“Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions (each, a “Sanctioned Country”); and the Company
will not, directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate
any activities of or business with any person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country that, at the time of such
funding or facilitation, are the subject or the target of Sanctions or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as initial purchaser, investor, advisor or
otherwise) of Sanctions; provided that, in the case of clauses (i) and (ii) above, the Company will not enter into any agreement to fund or facilitate any activities of or business (x) with any person that is the subject or the target of
Sanctions or (y) in any Sanctioned Country, in each case, at the time such agreement is signed. For the past 5 years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not knowingly engage in,
any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. 

  
 14 

 (hh) Solvency. On and immediately after the Closing Date, the Company and each
Guarantor (after giving effect to the issuance and sale of the Securities and the issuance of the related Guarantees and the other transactions related thereto as described in each of the Time of Sale Information and the Offering Memorandum) will be
Solvent. As used in this paragraph, the term “Solvent” means, with respect to a particular date and entity, that on such date (i) the present fair market value (and present fair saleable value) of the assets of such entity is
not less than the total amount required to pay the liabilities of such entity on its total existing debts and liabilities (including contingent liabilities) as they become absolute and matured; (ii) such entity is able to realize upon its assets and
pay its debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business; (iii) assuming consummation of the issuance and sale of the Securities and the issuance of the related
Guarantees as contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, such entity does not have, intend to incur or believe that it will incur debts or liabilities beyond its ability to pay as such debts and
liabilities mature; (iv) such entity is not engaged in any business or transaction, and does not propose to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to
the prevailing practice in the industry in which such entity is engaged; and (v) such entity is not a defendant in any civil action that would be reasonably likely to result in a judgment that such entity is or would become unable to satisfy. 

(ii) No Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement
or other instrument to which it is a party or is subject from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock or similar ownership interest, from repaying to the Company any loans or
advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company, except for any such restrictions (a) contained in the (i) Credit Agreement or
(ii) Existing Notes, which restrictions, in the case of clause (ii), if the Company receives the proceeds of the offering of the Securities, will be released and terminated on the Existing Notes Redemption Date, or, if earlier, upon the
satisfaction and discharge of the indenture governing the Existing Notes, or (b) that will be permitted by the Indenture. 
 (jj) No
Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Initial
Purchaser for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Securities that has not been previously disclosed to the Representative. 

(kk) Rule 144A Eligibility. On the Closing Date, the Securities will not be of the same class as securities listed on a national
securities exchange registered under Section 6 of the Exchange Act or quoted in an automated inter-dealer quotation system; and each of the Preliminary Offering Memorandum and the Offering Memorandum, as of its respective date, contains or will
contain all the information that, if requested by a prospective purchaser of the Securities, would be required to be provided to such prospective purchaser pursuant to Rule 144A(d)(4) under the Securities Act. 

  
 15 

 (ll) No Integration. Neither the Company nor any of its affiliates (as defined in
Rule 501(b) of Regulation D) has, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of
the Securities as contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum in a manner that would require registration of the Securities under the Securities Act. 

(mm) No General Solicitation or Directed Selling Efforts. None of the Company or any of its affiliates or any other person acting on
its or their behalf (other than the Initial Purchasers, as to which no representation is made) has (i) solicited offers for, or offered or sold, the Securities by means of any form of general solicitation or general advertising within the meaning of
Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act or (ii) engaged in any directed selling efforts within the meaning of Regulation S under the Securities Act
(“Regulation S”), and all such persons have complied with the offering restrictions requirement of Regulation S. 
 (nn)
Securities Law Exemptions. Assuming the accuracy of the representations and warranties of the Initial Purchasers contained in Section 1(b) (including Annex C hereto) and their compliance with their agreements set forth therein, it is not
necessary, in connection with the issuance and sale of the Securities to the Initial Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the manner contemplated by this Agreement, the Time of Sale Information
and the Offering Memorandum, to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act. 

(oo) No Stabilization. Neither the Company nor any of the Guarantors has taken, directly or indirectly, any action designed to or
that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. 
 (pp) Margin
Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described in each of the Time of Sale Information and the Offering Memorandum will violate Regulation T, U or X
of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. 
 (qq) Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Time of Sale Information or the Offering Memorandum
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 
 (rr) Industry Statistical and
Market Data. Nothing has come to the attention of the Company or any Guarantor that has caused the Company or such Guarantor to 

  
 16 

 
believe that the industry statistical and market-related data included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum is not based on or derived
from sources that are reliable and accurate in all material respects. 
 (ss) Sarbanes-Oxley Act. There is and has been no failure on
the part of the Company or, to the Company’s knowledge, any of the Company’s directors or officers, in their capacities as such, to comply, in all material respects, with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the
rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans and Sections 302 and 906 related to certifications. 

4. Further Agreements of the Company and the Guarantors. The Company and the Guarantors jointly and severally covenant and agree
with each Initial Purchaser that: 
 (a) Delivery of Copies. The Company will deliver, without charge, to the Initial Purchasers
as many copies of the Preliminary Offering Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments and supplements thereto) as the Representative may reasonably request.

 (b) Offering Memorandum, Amendments or Supplements. Before finalizing the Offering Memorandum or making or distributing any
amendment or supplement to any of the Time of Sale Information or the Offering Memorandum or filing with the Commission any document that will be incorporated by reference therein, the Company will furnish to the Representative and counsel for the
Initial Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement or document to be incorporated by reference therein for review, and will not distribute any such proposed Offering Memorandum, amendment or supplement or
file any such document with the Commission to which the Representative reasonably objects. 
 (c) Additional Written
Communications. Before making, preparing, using, authorizing, approving or referring to any Issuer Written Communication, the Company and the Guarantors will furnish to the Representative and counsel for the Initial Purchasers a copy of
such written communication for review and will not make, prepare, use, authorize, approve or refer to any such written communication to which the Representative reasonably objects. 

(d) Notice to the Representative. The Company will advise the Representative promptly, and confirm such advice in writing, (i) of
the issuance by any governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or the initiation or threatening of any
proceeding for that purpose; (ii) of the occurrence of any event at any time prior to the completion of the initial offering of the Securities as a result of which any of the Time of Sale Information, any Issuer Written Communication or the Offering
Memorandum, in each case, as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the

  
 17 

 
circumstances existing when such Time of Sale Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser, not misleading; and (iii) of the receipt by the
Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its commercially
reasonable efforts to prevent the issuance of any such order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the Securities
and, if any such order is issued, will obtain as soon as possible the withdrawal thereof. 
 (e) Time of Sale
Information. If at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a result of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii) it is necessary to amend or supplement the Time of Sale
Information to comply with law, the Company will immediately notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to the Time of Sale
Information (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in any of the Time of Sale Information as so amended or supplemented (including such documents to be
incorporated by reference therein) will not, in the light of the circumstances under which they were made, be misleading or so that any of the Time of Sale Information will comply with law. 

(f) Ongoing Compliance of the Offering Memorandum. If at any time prior to the completion of the initial offering of the
Securities (i) any event shall occur or condition shall exist as a result of which the Offering Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements therein, in the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Offering Memorandum to comply with law, the Company
will immediately notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to the Offering Memorandum (or any document to be filed with the
Commission and incorporated by reference therein) as may be necessary so that the statements in the Offering Memorandum as so amended or supplemented (including such document to be incorporated by reference therein) will not, in the light of the
circumstances existing when the Offering Memorandum is delivered to a purchaser, be misleading or so that the Offering Memorandum will comply with law. 

(g) Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such
jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required for the offering and resale of the Securities; provided that neither the Company nor any of the Guarantors shall
be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such
jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject. 

  
 18 

 (h) Clear Market. During the period from the date hereof through and including the
date that is 90 days after the date hereof, the Company and each of the Guarantors will not, without the prior written consent of the Representative, offer, sell, contract to sell or otherwise dispose of any debt securities issued or guaranteed by
the Company or any of the Guarantors and having a tenor of more than one year. 
 (i) Use of Proceeds. The Company will apply the net
proceeds from the sale of the Securities as described in each of the Time of Sale Information and the Offering Memorandum under the heading “Use of proceeds”. 

(j) Supplying Information. While the Securities remain outstanding and are “restricted securities” within the meaning of Rule
144(a)(3) under the Securities Act, the Company and each of the Guarantors will, during any period in which the Company is not subject to, and in compliance with, Section 13 or 15(d) of the Exchange Act, furnish to holders of the Securities and
prospective purchasers of the Securities designated by such holders, upon the request of such holders or such prospective purchasers, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 

(k) DTC. The Company will reasonably assist the Initial Purchasers in arranging for the Securities to be eligible for clearance
and settlement through DTC. 
 (l) No Resales by the Company. Until consummation of the exchange offer as contemplated by the
Registration Rights Agreement, the Company will not, and will not permit any of its affiliates (as defined in Rule 144 under the Securities Act) to, resell any of the Securities that have been acquired by any of them, except for Securities purchased
by the Company or any of its affiliates and resold in a transaction registered under the Securities Act. 
 (m) No
Integration. Neither the Company nor any of its affiliates (as defined in Rule 501(b) of Regulation D) will, directly or through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any security (as
defined in the Securities Act), that is or will be integrated with the sale of the Securities as contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum in a manner that would require registration of the Securities
under the Securities Act. 
 (n) No General Solicitation or Directed Selling Efforts. None of the Company or any of its
affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as to which no covenant is given) will (i) solicit offers for, or offer or sell, the Securities by means of any form of general solicitation or general
advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act or (ii) engage in any directed selling efforts within the meaning of Regulation S,
and all such persons will comply with the offering restrictions requirement of Regulation S. 

  
 19 

 (o) No Stabilization. Neither the Company nor any of the Guarantors will take,
directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. 

5. Certain Agreements of the Initial Purchasers. Each Initial Purchaser hereby represents and agrees that it has not and will not use,
authorize use of, refer to, or participate in the planning for use of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i) the Preliminary Offering Memorandum and the
Offering Memorandum, (ii) any written communication that contains either (a) no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) or (b) “issuer information” that was included (including through
incorporation by reference) in the Time of Sale Information or the Offering Memorandum, (iii) any written communication listed on Annex A or prepared in accordance with Section 4(c) above (including any electronic road show), (iv) any written
communication prepared by such Initial Purchaser and approved by the Company in advance in writing or (v) any written communication relating to or that contains the terms of the Securities and/or other information that was included (including
through incorporation by reference) in the Time of Sale Information or the Offering Memorandum. 
 6. Conditions of Initial
Purchasers’ Obligations. The obligation of each Initial Purchaser to purchase Securities on the Closing Date as provided herein is subject to the performance by the Company and each of the Guarantors of their respective covenants and
other obligations hereunder and to the following additional conditions: 
 (a) Representations and Warranties. The
representations and warranties of the Company and the Guarantors contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company, the Guarantors and their respective officers made in
any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. 
 (b) No Downgrade.
Subsequent to the earlier of (A) the Time of Sale and (B) the execution and delivery of this Agreement, (i) no downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock issued or guaranteed
by the Company or any of its subsidiaries by any “nationally recognized statistical rating organization”, as such term is defined under Section 3(a)(62) under the Exchange Act and (ii) no such organization shall have publicly announced
that it has under surveillance or review, or has changed its outlook with respect to, its rating of the Securities or of any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an
announcement with positive implications of a possible upgrading or an “under criteria observation” identifier assigned in accordance with Standard & Poor’s Ratings Services’ announcement dated November 13, 2013 of its
intention to publish revised criteria for determining certain issuer credit ratings). 
 (c) No Material Adverse Change. No
event or condition of a type described in Section 3(e) hereof shall have occurred or shall exist, which event or condition is not described in each of the Time of Sale Information (excluding any amendment or

  
 20 

 
supplement thereto) and the Offering Memorandum (excluding any amendment or supplement thereto) the effect of which in the judgment of the Representative makes it impracticable or inadvisable to
proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum. 

(d) Officer’s Certificate. The Representative shall have received on and as of the Closing Date a certificate of an executive
officer (solely in his or her official capacity) of the Company and of each Guarantor who has specific knowledge of the financial matters of the Company or such Guarantor, as applicable, and is satisfactory to the Representative (i) confirming that
such officer has carefully reviewed the Time of Sale Information and the Offering Memorandum and, to the knowledge of such officer, the representations set forth in Sections 3(a) and 3(b) hereof are true and correct, (ii) confirming that the other
representations and warranties of the Company and the Guarantors in this Agreement are true and correct and that the Company and the Guarantors have complied with all agreements and satisfied all conditions on their part to be performed or satisfied
hereunder at or prior to the Closing Date and (iii) to the effect set forth in the immediately preceding paragraphs (b) and (c) above. 

(e) Comfort Letters. On the date of this Agreement and on the Closing Date, Grant Thornton LLP shall have furnished to the
Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative, containing statements and
information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Time of
Sale Information and the Offering Memorandum; provided that the letters delivered on the Closing Date shall use a “cut-off” date no more than three business days prior to the Closing Date. 

(f) Opinion and 10b-5 Statement of Counsel for the Company. Akin Gump Strauss Hauer & Feld LLP, counsel for the Company, shall
have furnished to the Representative, at the request of the Company, its written opinion and 10b-5 statement, dated the Closing Date and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative, to the
effect set forth in Annex D hereto. 
 (g) Opinions of Local Counsel. (i) Conner & Winters, LLP, counsel for Atlas-Tuck Concrete,
Inc. (the “Oklahoma Guarantor”) in the State of Oklahoma, shall have furnished to the Representative, at the request of the Company, its written opinion, dated the Closing Date and addressed to the Initial Purchasers, in form and substance
reasonably satisfactory to the Representative, to the effect set forth in Annex E hereto; (ii) Connell Foley LLP, counsel for 160 East 22nd Terminal, LLC, Colonial Concrete, Co., Eastern Concrete Materials, Inc., Ferrara West LLC, Hamburg Quarry
Limited Liability Company, Master Mix Concrete, LLC, and Premco Organization, Inc. (the “New Jersey Guarantors”) in the State of New Jersey, shall have furnished to the Representative, at the request of the Company, its written opinion,
dated the Closing Date and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative, to the effect set forth in Annex F hereto; (iii) Honigman Miller 

  
 21 

 
Schwartz and Cohn LLP, counsel for Kurtz Gravel Company (the “Michigan Guarantor”) in the State of Michigan, shall have furnished to the Representative, at the request of the Company,
its written opinion, dated the Closing Date and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representative, to the effect set forth in Annex G hereto; and (iv) McKennon Shelton & Henn LLP,
counsel for MG, LLC (the “Maryland Guarantor”) in the State of Maryland, shall have furnished to the Representative, at the request of the Company, its written opinion, dated the Closing Date and addressed to the Initial Purchasers, in
form and substance reasonably satisfactory to the Representative, to the effect set forth in Annex H hereto. 
 (h) Opinion and 10b-5
Statement of Counsel for the Initial Purchasers. The Representative shall have received on and as of the Closing Date an opinion and 10b-5 statement, addressed to the Initial Purchasers, of Cravath, Swaine & Moore LLP, counsel for the
Initial Purchasers, with respect to such matters as the Representative may reasonably request, and such counsel shall have received such documents and information as it may reasonably request to enable it to pass upon such matters. 

(i) No Legal Impediment to Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been
enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees; and no injunction or order of any
federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees. 

(j) Good Standing. The Representative shall have received on and as of the Closing Date satisfactory evidence of the good standing
of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representative may reasonably request, in each case, in writing or any standard form of
telecommunication from the appropriate governmental authorities of such jurisdictions. 
 (k) Registration Rights Agreement. The
Initial Purchasers shall have received a counterpart of the Registration Rights Agreement that shall have been executed and delivered by a duly authorized officer of the Company and each of the Guarantors. 

(l) DTC. The Securities shall be eligible for clearance and settlement through DTC. 

(m) Indenture and Securities. The Indenture shall have been duly executed and delivered by a duly authorized officer of the
Company, each of the Guarantors and the Trustee and the Securities shall have been duly executed and delivered by a duly authorized officer of the Company and duly authenticated by the Trustee. 

(n) Existing Indebtedness. The Representative shall have received evidence reasonably satisfactory to it that, (i) prior to the
purchase of the Securities by the Initial Purchasers, the Company has issued the Existing Notes Redemption Notice, (ii) subject to receipt of the proceeds of the offering of the Securities, the Company shall make the

  
 22 

 
Existing Notes Redemption Deposit on or promptly after the Closing Date, and (iii) proceeds of the offering of the Securities will be used to repay all outstanding borrowings under the
Company’s asset-based senior secured revolving credit facility. 
 (o) Transaction. Concurrently with or prior to the
Closing Date, the Transactions shall have been consummated in a manner consistent in all material respects with the descriptions thereof in the Time of Sale Information and the Offering Memorandum. 

(p) Additional Documents. On or prior to the Closing Date, the Company and the Guarantors shall have furnished to the
Representative such further certificates and documents as the Representative may reasonably request. 
 All opinions, letters, certificates
and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Initial Purchasers. 

7. Indemnification and Contribution. 

(a) Indemnification of the Initial Purchasers. The Company and each of the Guarantors, jointly and severally, agree to indemnify
and hold harmless each Initial Purchaser, its affiliates, directors and officers and each person, if any, who controls such Initial Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against
any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses reasonably incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred),
joint or several, that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication
or the Offering Memorandum or any amendment or supplement thereto or any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading, in each case, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in the Preliminary Offering Memorandum, any of
the other Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or any amendment or supplement thereto in reliance upon, and in conformity with, any information relating to any Initial Purchaser furnished to the
Company in writing by such Initial Purchaser through the Representative expressly for use therein. 
 (b) Indemnification of the Company
and the Guarantors. Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company, each of the Guarantors, each of their respective directors and officers and each person, if any, who controls the
Company or any of the Guarantors within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims,

  
 23 

 
damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon, and in conformity with, any
information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representative expressly for use in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer
Written Communication or the Offering Memorandum (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the following information in the Preliminary Offering Memorandum and the Offering
Memorandum: (i) the third, fourth and fifth sentences of the second paragraph, (ii) the fourth and fifth sentences of the eighteenth paragraph, (iii) the twentieth paragraph, (iv) the twenty-first paragraph and (v) the last sentence of the
twenty-second paragraph, in each case, under the caption “Plan of distribution”. 
 (c) Notice and Procedures. If any suit,
action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above, such person
(the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person
shall not relieve it from any liability that it may have under paragraph (a) or (b) above, except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided,
further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph (a) or (b) above. If any such proceeding shall be brought or
asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified
Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section 7 that the Indemnifying Person may designate in such proceeding and shall pay the fees and
expenses of such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of
such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain
counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the
Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due
to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses
of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be reimbursed as they are incurred. Any such separate firm for any Initial Purchaser, its affiliates,
directors and officers and any control persons of such Initial Purchaser shall be designated in writing by J.P. Morgan Securities 

  
 24 

 
LLC and any such separate firm for the Company, the Guarantors, their respective directors and officers and any control persons of the Company and the Guarantors shall be designated in writing by
the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person
agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any
pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release
of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault,
culpability or a failure to act by or on behalf of any Indemnified Person. 
 (d) Contribution. If the indemnification provided
for in paragraph (a) or (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such
Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by
the Company and the Guarantors on the one hand and the Initial Purchasers on the other from the offering of the Securities or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company and the Guarantors on the one hand and the Initial Purchasers on the other in connection with the statements or omissions that resulted in
such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Guarantors on the one hand and the Initial Purchasers on the other shall be deemed to be in
the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Securities and the total discounts and commissions received by the Initial Purchasers in connection therewith, as provided
in this Agreement, bear to the aggregate offering price of the Securities. The relative fault of the Company and the Guarantors on the one hand and the Initial Purchasers on the other shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or any Guarantor or by the Initial Purchasers and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e) Limitation on
Liability. The Company, the Guarantors and the Initial Purchasers agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Initial Purchasers
were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of
the losses, claims, 

  
 25 

 
damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person
in connection with any such action or claim. Notwithstanding the provisions of this Section 7, in no event shall an Initial Purchaser be required to contribute any amount in excess of the amount by which the total discounts and commissions received
by such Initial Purchaser with respect to the offering of the Securities exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial
Purchasers’ obligations to contribute pursuant to this Section 7 are several in proportion to their respective purchase obligations hereunder and not joint. 

(f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and shall not limit any rights or
remedies that may otherwise be available to any Indemnified Person at law or in equity. 
 8. Termination. This Agreement may be
terminated in the absolute discretion of the Representative, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading generally shall have been suspended or materially limited on
the New York Stock Exchange or The NASDAQ Stock Market or the over-the-counter market; (ii) trading of any securities issued or guaranteed by the Company or any of the Guarantors shall have been suspended on any exchange or in any over-the-counter
market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or
any calamity or crisis, either within or outside the United States, that, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on
the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum. 
 9. Defaulting
Initial Purchaser. 
 (a) If, on the Closing Date, any Initial Purchaser defaults on its obligation to purchase the Securities that it
has agreed to purchase hereunder, the non-defaulting Initial Purchasers may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours
after any such default by any Initial Purchaser, the non-defaulting Initial Purchasers do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within which to procure other persons
satisfactory to the non-defaulting Initial Purchasers to purchase such Securities on such terms. If other persons become obligated or agree to purchase the Securities of a defaulting Initial Purchaser, either the
non-defaulting Initial Purchasers or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that, in the opinion of counsel for the Company or counsel for
the Initial Purchasers, may be necessary in the Time of Sale Information, the Offering Memorandum or in any other 

  
 26 

 
document or arrangement and the Company agrees to promptly prepare any amendment or supplement to the Time of Sale Information or the Offering Memorandum that effects any such changes. As used in
this Agreement, the term “Initial Purchaser” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 9, purchases Securities that a
defaulting Initial Purchaser agreed but failed to purchase. 
 (b) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased does not
exceed one-eleventh of the aggregate principal amount of all the Securities, then the Company shall have the right to require each non-defaulting Initial Purchaser to purchase the principal amount of Securities that such Initial Purchaser agreed to
purchase hereunder plus such Initial Purchaser’s pro rata share (based on the principal amount of Securities that such Initial Purchaser agreed to purchase hereunder) of the Securities of such defaulting Initial Purchaser or
Initial Purchasers for which such arrangements have not been made. 
 (c) If, after giving effect to any arrangements for the purchase of
the Securities of a defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased exceeds
one-eleventh of the aggregate principal amount of all the Securities, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement shall terminate without liability on the part of the non-defaulting Initial
Purchasers. Any termination of this Agreement pursuant to this Section 9 shall be without liability on the part of the Company or the Guarantors, except that the Company and each of the Guarantors will continue to be liable for the payment of
expenses as set forth in Section 10 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect. 

(d) Nothing contained herein shall relieve a defaulting Initial Purchaser of any liability it may have to the Company, the Guarantors or any
non-defaulting Initial Purchaser for damages caused by its default. 
 10. Payment of Expenses. 

(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company and each of
the Guarantors jointly and severally agree to pay or cause to be paid all costs and expenses incident to the performance of their respective obligations hereunder, including without limitation, (i) the costs incident to the authorization,
issuance, sale, preparation and delivery of the Securities and any stamp, transfer or similar taxes payable in that connection; (ii) the costs incident to the preparation and printing of the Preliminary Offering Memorandum, any other Time of
Sale Information, any Issuer Written Communication and the Offering Memorandum (including any amendment or supplement thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of the Transaction Documents; (iv)
the fees and expenses of the Company’s and the Guarantors’ counsel and 

  
 27 

 
independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws
of such jurisdictions as the Representative may designate and the preparation, printing and distribution of a Blue Sky memorandum (including the related fees and expenses of counsel for the Initial Purchasers); (vi) any fees charged by rating
agencies for rating the Securities; (vii) the fees and expenses of the Trustee and any paying agent (including related fees and expenses of any counsel to such parties); (viii) all expenses and application fees incurred in connection with the
approval of the Securities for book-entry transfer by DTC; and (ix) all expenses incurred by the Company in connection with any “road show” presentation to potential investors. 

(b) If (i) this Agreement is terminated pursuant to Section 8 hereof, (ii) the Company for any reason fails to tender the Securities for
delivery to the Initial Purchasers or (iii) the Initial Purchasers decline to purchase the Securities for any reason permitted under this Agreement, the Company and each of the Guarantors jointly and severally agree to reimburse the Initial
Purchasers for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Initial Purchasers in connection with this Agreement and the offering contemplated hereby. 

11. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto
and their respective successors and the officers and directors and any controlling persons referred to herein and the affiliates of each Initial Purchaser referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be
construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor
merely by reason of such purchase. 
 12. Survival. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company, the Guarantors and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company, the Guarantors or the Initial Purchasers pursuant to this Agreement or any certificate delivered
pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company, the Guarantors or the
Initial Purchasers. 
 13. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the
term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; (c)
the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act; (d) the term “Exchange Act” means the Securities Exchange Act of 1934, as amended; and (e) the term “written
communication” has the meaning set forth in Rule 405 under the Securities Act. 
 14. Compliance with USA PATRIOT
Act. In accordance with the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law 

  
 28 

 
October 26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the
name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

15. Miscellaneous. 
 (a)
Authority of the Representative. Any action by the Initial Purchasers hereunder may be taken by J.P. Morgan Securities LLC on behalf of the Initial Purchasers, and any such action taken by J.P. Morgan Securities LLC shall be binding upon
the Initial Purchasers. 
 (b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed
to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Representative c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New
York 10179 (fax: 212-270-1063); Attention: Geoffrey Benson. Notices to the Company and the Guarantors shall be given to Paul M. Jolas, Vice President, General Counsel & Corporate Secretary, 331 N. Main Street, Euless, Texas 76039 (fax:
817-835-4165). 
 (c) Governing Law. This Agreement and any claim, controversy or dispute arising under, or related to, this
Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. 
 (d) Submission to
Jurisdiction. The Company and each of the Guarantors hereby submit to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit, action or proceeding arising out
of, or relating to, this Agreement or the transactions contemplated hereby. The Company and each of the Guarantors waive any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such
courts. Each of the Company and each of the Guarantors agrees that a final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and each Guarantor, as applicable, and may be
enforced in any court to the jurisdiction of which the Company and each Guarantor, as applicable, is subject by a suit upon such judgment. 

(e) Waiver of Jury Trial. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding
arising out of, or relating to, this Agreement. 
 (f) Counterparts. This Agreement may be signed in counterparts (which may
include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. 

(g) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. 

  
 29 

 (h) Headings. The headings herein are included for convenience of reference only and
are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. 

  
 30 

 If the foregoing is in accordance with your understanding, please indicate your acceptance of
this Agreement by signing in the space provided below. 
  

			
	Very truly yours,
	
	U.S. CONCRETE, INC.
		
	By:	 	/s/ William J. Sandbrook
	Name:	 	William J. Sandbrook
	Title:	 	President and Chief Executive Officer

  

			
	 CUSTOM-CRETE, LLC
 REDI-MIX,
LLC

		
	By:	 	/s/ William J. Sandbrook
	Name:	 	William J. Sandbrook
	Title:	 	Vice President

  

			
	OUTRIGGER, LLC
		
	By:	 	/s/ William J. Sandbrook
	Name:	 	William J. Sandbrook
	Title:	 	President

 (Signature Page to Purchase Agreement) 

 
			
	HAMBURG QUARRY LIMITED LIABILITY COMPANY
		
	By:	 	/s/ Kevin R. Kohutek
	Name:	 	Kevin R. Kohutek
	Title:	 	President
	
	 160 EAST 22ND TERMINAL LLC

AGGREGATE & CONCRETE TESTING, LLC
 COLONIAL CONCRETE CO.

EASTERN CONCRETE MATERIALS, INC.
 FERRARA BROS., LLC

FERRARA WEST LLC
 LOCAL
CONCRETE SUPPLY & EQUIPMENT,
 LLC

MASTER MIX CONCRETE, LLC
 MASTER MIX, LLC

MG, LLC
 NEW YORK SAND & STONE, LLC

NYC CONCRETE MATERIALS, LLC
 PEBBLE LANE ASSOCIATES, LLC

PREMCO ORGANIZATION, INC.
 SUPERIOR CONCRETE MATERIALS, INC.

USC ATLANTIC, INC.

  

			
		
	By:	 	/s/ Kevin R. Kohutek
	Name:	 	Kevin R. Kohutek
	Title:	 	Vice President

 (Signature Page to Purchase Agreement) 

 
			
	YARDARM, LLC
		
	By:	 	 /s/ Paul M. Jolas

	Name:	 	Paul M. Jolas
	Title:	 	Secretary

 (Signature Page to Purchase Agreement) 

 
			
	 ALBERTA INVESTMENTS, INC.
 ALLIANCE
HAULERS, INC.
 ATLAS REDI-MIX, LLC
 ATLAS-TUCK CONCRETE,
INC.
 BEALL CONCRETE ENTERPRISES, LLC
 BEALL INDUSTRIES,
INC.
 BEALL INVESTMENT CORPORATION, INC.
 BEALL MANAGEMENT,
INC.
 CUSTOM-CRETE REDI-MIX, LLC
 REDI-MIX CONCRETE, L.P.

REDI-MIX GP, LLC
 RIGHT AWAY REDY MIX INCORPORATED

ROCK TRANSPORT, INC.
 TITAN CONCRETE INDUSTRIES, INC.

USC PAYROLL, INC.
 U.S. CONCRETE ON-SITE, INC.

		
	By:	 	 /s/ Ronnie Pruitt

	Name:	 	Ronnie Pruitt
	Title:	 	President

  

			
	 AMERICAN CONCRETE PRODUCTS, INC.

BODE CONCRETE LLC
 BODE GRAVEL CO.

BRECKENRIDGE READY MIX, INC.
 CENTRAL CONCRETE SUPPLY CO.,
INC.
 CENTRAL PRECAST CONCRETE, INC.
 INGRAM CONCRETE, LLC

KURTZ GRAVEL COMPANY
 RIVERSIDE MATERIALS, LLC

SAN DIEGO PRECAST CONCRETE, INC.
 SIERRA PRECAST, INC.

SMITH PRE-CAST, INC.

		
	By:	 	 /s/ Ronnie Pruitt

	Name:	 	Ronnie Pruitt
	Title:	 	Vice President

 (Signature Page to Purchase Agreement) 

 
			
	 CONCRETE XXXIV ACQUISITION, INC.

CONCRETE XXXV ACQUISITION, INC.
 CONCRETE XXXVI ACQUISITION,
INC.
 USC MANAGEMENT CO., LLC
 USC TECHNOLOGIES, INC.

U.S. CONCRETE TEXAS HOLDINGS, INC.

		
	By:	 	 /s/ Ronnie Pruitt

	Name:	 	Ronnie Pruitt
	Title:	 	Treasurer

 (Signature Page to Purchase Agreement) 

			
	 Accepted: May 23, 2016
  

J.P. MORGAN SECURITIES LLC

	   For itself and on behalf of the

  several Initial Purchasers listed
   in
Schedule 1 hereto.

		
	By	 	 /s/ Brian Tramontozzi

		 	Authorized Signatory

 (Signature Page to Purchase Agreement) 

 Schedule 1 
  

					
	 Initial Purchaser
	  	 Principal Amount
	 
	 J.P. Morgan Securities LLC
	  	$	260,000,000	  
	 UBS Securities LLC
	  	$	80,000,000	  
	 RBC Capital Markets, LLC.
	  	$	20,000,000	  
	 SunTrust Robinson Humphrey, Inc.
	  	$	20,000,000	  
	 Capital One Securities, Inc.
	  	$	10,000,000	  
	 Mitsubishi UFJ Securities (USA), Inc.
	  	$	10,000,000	  
	 Total
	  	$	400,000,000	  

 Schedule 2 

Guarantors 
 160 East 22nd Terminal LLC 

Aggregate & Concrete Testing, LLC 
 Alberta Investments, Inc.

 Alliance Haulers, Inc. 
 American Concrete Products, Inc.

 Atlas Redi-Mix, LLC 
 Atlas-Tuck Concrete, Inc. 

Beall Concrete Enterprises, LLC 
 Beall Industries, Inc. 

Beall Investment Corporation, Inc. 
 Beall Management, Inc. 

Bode Concrete LLC 
 Bode Gravel Co. 

Breckenridge Ready Mix, Inc. 
 Central Concrete Supply Co., Inc.

 Central Precast Concrete, Inc. 
 Colonial Concrete Co. 

Concrete XXXIV Acquisition, Inc. 
 Concrete XXXV Acquisition, Inc.

 Concrete XXXVI Acquisition, Inc. 
 Custom-Crete, LLC 

Custom-Crete Redi-Mix, LLC 
 Eastern Concrete Materials, Inc. 

Ferrara Bros., LLC 
 Ferrara West LLC 

Hamburg Quarry Limited Liability Company 
 Ingram Concrete, LLC

 Kurtz Gravel Company 
 Local Concrete Supply & Equipment,
LLC 
 Master Mix, LLC 
 Master Mix Concrete, LLC 

MG, LLC 
 New York Sand & Stone, LLC 

NYC Concrete Materials, LLC 
 Outrigger, LLC 

Pebble Lane Associates, LLC 
 Premco Organization, Inc. 

Redi-Mix Concrete, L.P. 
 Redi-Mix GP, LLC 

Redi-Mix, LLC 
 Right Away Redy Mix Incorporated 

Riverside Materials, LLC 
 Rock Transport, Inc. 

San Diego Precast Concrete, Inc. 
 Sierra Precast, Inc. 

 Smith Pre-Cast, Inc. 

Superior Concrete Materials, Inc. 
 Titan Concrete Industries,
Inc. 
 USC Atlantic, Inc. 
 USC Management Co., LLC 

USC Payroll, Inc. 
 USC Technologies, Inc. 

U.S. Concrete On-Site, Inc. 
 U.S. Concrete Texas Holdings, Inc.

 Yardarm, LLC 

 Schedule 3 

Subsidiaries 
 160 East 22nd Terminal LLC 

Aggregate & Concrete Testing, LLC 
 Alberta Investments, Inc.

 Alliance Haulers, Inc. 
 American Concrete Products, Inc.

 Atlas Redi-Mix, LLC 
 Atlas-Tuck Concrete, Inc. 

Beall Concrete Enterprises, LLC 
 Beall Industries, Inc. 

Beall Investment Corporation, Inc. 
 Beall Management, Inc. 

Bode Concrete LLC 
 Bode Gravel Co. 

Breckenridge Ready Mix, Inc. 
 Central Concrete Supply Co., Inc.

 Central Precast Concrete, Inc. 
 Colonial Concrete Co. 

Concrete XXXIV Acquisition, Inc. 
 Concrete XXXV Acquisition, Inc.

 Concrete XXXVI Acquisition, Inc. 
 Custom-Crete, LLC 

Custom-Crete Redi-Mix, LLC 
 Eastern Concrete Materials, Inc. 

Ferrara Bros., LLC 
 Ferrara West LLC 

Hamburg Quarry Limited Liability Company 
 Heavy Materials, LLC

 Ingram Concrete, LLC 
 Kurtz Gravel Company 

Local Concrete Supply & Equipment, LLC 
 Master Mix, LLC 

Master Mix Concrete, LLC 
 MG, LLC 

New York Sand & Stone, LLC 
 NYC Concrete Materials, LLC 

Outrigger, LLC 
 Pebble Lane Associates, LLC 

Premco Organization, Inc. 
 Redi-Mix Concrete, L.P. 

Redi-Mix GP, LLC 
 Redi-Mix, LLC 

Right Away Redy Mix Incorporated 
 Riverside Materials, LLC 

Rock Transport, Inc. 
 San Diego Precast Concrete, Inc. 

Sierra Precast, Inc. 

 Smith Pre-Cast, Inc. 

Spartan Products, LLC 
 Superior Concrete Materials, Inc. 

Titan Concrete Industries, Inc. 
 USC Atlantic, Inc. 

USC Management Co., LLC 
 USC Payroll, Inc. 

USC Technologies, Inc. 
 U.S. Concrete On-Site, Inc. 

U.S. Concrete Texas Holdings, Inc. 
 Yardarm, LLC 

 ANNEX A 

Additional Time of Sale Information 

1. Term sheet containing the terms of the Securities, substantially in the form of Annex B. 

 ANNEX B 

Pricing Term Sheet, dated May 23, 2016 

to Preliminary Offering Memorandum dated May 17, 2016 

Strictly Confidential 

U.S. Concrete, Inc. 
 This pricing term
sheet is made with reference to the Preliminary Offering Memorandum (the “Preliminary Offering Memorandum”). The information in this pricing term sheet supplements the Preliminary Offering Memorandum and updates and supersedes the
information in the Preliminary Offering Memorandum to the extent it is inconsistent with the information in the Preliminary Offering Memorandum. Terms used and not defined herein have the meanings assigned in the Preliminary Offering Memorandum.

 The notes have not been registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction. The notes may not be
offered or sold in the United States or to U.S. persons (as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. Accordingly, the notes are being offered only (1) to
“qualified institutional buyers” as defined in Rule 144A under the Securities Act and (2) outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. 

 

					
	Issuer:	  	U.S. Concrete, Inc.
	Security description:	  	Senior Notes
	Distribution:	  	144A/Reg S registration rights
	Size:	  	$400,000,000
	Gross proceeds:	  	$400,000,000
	Maturity:	  	June 1, 2024
	Coupon:	  	6.375%
	Issue price:	  	100.000% of face amount.
	Yield to maturity:	  	6.375%
	Spread to Benchmark Treasury:	  	+452bps
	Benchmark Treasury:	  	UST 2.5% due May 15, 2024
	Interest Payment Dates:	  	June 1 and December 1, commencing December 1, 2016
	Equity clawback:	  	Up to 35% at 106.375% prior to June 1, 2019
	Optional redemption:	  	 Make-whole call @ T+50bps prior to June 1, 2019 then:

			
	 	  	 On or after:
	  	 Price:

		  	June 1, 2019	  	104.781%
		  	June 1, 2020	  	103.188%
		  	June 1, 2021	  	101.594%
		  	June 1, 2022 and thereafter	  	100.000%
	Change of control:	  	Putable at 101% of principal plus accrued and unpaid interest

					
	Trade date:	  	May 23, 2016
	Settlement:	  	T+10; June 7, 2016.
	CUSIP:	  	 144A: CUSIP No. 90333LAM4

REG S: CUSIP No. U9033EAE8

	ISIN:	  	 144A: ISIN No. US90333LAM46

REG S: ISIN No. USU9033EAE87

	Denominations/Multiple:	  	$2,000 x $1,000
	Ratings*:	  	B3/BB-
	Book-Running Managers:	  	 J.P. Morgan Securities LLC
 UBS
Securities LLC

	Senior Co-Managers:	  	 RBC Capital Markets, LLC

SunTrust Robinson Humphrey, Inc.

	Co-Managers:	  	Capital One Securities, Inc.
		  	Mitsubishi UFJ Securities (USA), Inc.

 Use of Proceeds 

Estimated net proceeds to the Issuer from the offering of notes will be approximately $392.5 million, after deducting the Initial Purchasers’ discounts
and commissions and estimated offering expenses. 
  

This material is confidential and is for your information only and is not intended to be used by anyone other than you. This information does not purport
to be a complete description of these notes or the offering. Please refer to the Preliminary Offering Memorandum for a complete description. 
 This
communication is being distributed in the United States solely to Qualified Institutional Buyers, as defined in Rule 144A under the Securities Act of 1933, as amended, and outside the United States solely to Non-U.S. persons as defined under
Regulation S. 
 This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to
any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. 
  

	*A	securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. 

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. 

 ANNEX C 

Restrictions on Offers and Sales Outside the United States 

In connection with offers and sales of Securities outside the United States: 

(a) Each Initial Purchaser acknowledges that the Securities have not been registered under the Securities Act and may not be offered or sold
within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in transactions not subject to, the registration requirements of the Securities Act. 

(b) Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 

(i) Such Initial Purchaser has offered and sold the Securities, and will offer and sell the Securities, (A) as part of their
distribution at any time and (B) otherwise until 40 days after the later of the commencement of the offering of the Securities and the Closing Date, in each case, only in accordance with Regulation S under the Securities Act (“Regulation
S”) or Rule 144A or any other available exemption from registration under the Securities Act. 
 (ii) None of such
Initial Purchaser or any of its affiliates or any other person acting on its or their behalf has engaged or will engage in any directed selling efforts with respect to the Securities, and all such persons have complied and will comply with the
offering restrictions requirement of Regulation S. 
 (iii) At or prior to the confirmation of sale of any Securities sold in
reliance on Regulation S, such Initial Purchaser will have sent to each distributor, dealer or other person receiving a selling concession, fee or other remuneration that purchases Securities from it during the distribution compliance period a
confirmation or notice to substantially the following effect: 
 “The Securities covered hereby have not been registered under the U.S.
Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or (ii) otherwise
until 40 days after the later of the commencement of the offering of the Securities and the date of original issuance of the Securities, in each case, except in accordance with Regulation S or Rule 144A or any other available exemption from
registration under the Securities Act. Terms used above have the meanings given to them by Regulation S.” 
 (iv) Such
Initial Purchaser has not and will not enter into any contractual arrangement with any distributor with respect to the distribution of the Securities, except with its affiliates or with the prior written consent of the Company. 

 Terms used in paragraph (a) and this paragraph (b) and not otherwise defined in this Agreement have the meanings
given to them by Regulation S. 
 (c) Each Initial Purchaser acknowledges that no action has been or will be taken by the Company that would
permit a public offering of the Securities or possession or distribution of any of the Time of Sale Information, the Offering Memorandum, any Issuer Written Communication or any other offering or publicity material relating to the Securities, in
each case, in any country or jurisdiction where action for that purpose is required. 
 (d) Each Initial Purchaser, severally and not
jointly, represents, warrants and agrees that: 
 (i) it has only communicated or caused to be communicated and will only communicate or
cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the “FSMA”)) received by it in connection with the issue or
sale of any Securities in circumstances in which Section 21(1) of the FSMA does not apply to the Company; and 
 (ii) it has complied and
will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Securities in, from or otherwise involving the United Kingdom.EX-4.2

 Exhibit 4.2 

STOCKHOLDERS’ AGREEMENT 

THIS STOCKHOLDERS’ AGREEMENT (as amended, supplemented or restated from time to time, this “Agreement”) is
entered into as of [●], 2016 (the “Effective Date”), by and among NantHealth, Inc. (the “Company”) and those stockholders of the Company set forth on Schedule A attached hereto (each a
“Holder” and collectively the “Holders”). 
 RECITALS 

A. Nant Health, LLC (the “LLC”) was formed as a limited liability company under the Delaware Limited Liability Company Act (6
Del. C. Section 18-101, et seq.) pursuant to the filing of a Certificate of Formation with the Delaware Secretary of State on July 7, 2010. 

B. NantWorks, LLC, a Delaware limited liability company (“NantWorks”), as the then sole member of the LLC, previously
executed a Second Amendment to and Restatement of Limited Liability Company Agreement for the LLC dated January 6, 2012 (the “Original Agreement”). 

C. NantWorks and Verizon Investments LLC, a Delaware limited liability company (“Verizon”), amended and restated the Original
Agreement by executing an amended and restated limited liability company agreement for the LLC dated October 2, 2012 (the “First Restated Agreement”) in connection with Verizon’s investment in the LLC and acquisition of
Series B Units of the LLC (the “Series B Units”). 
 D. NantWorks and Celgene Corporation, a Delaware corporation
(“Celgene”), amended and restated the First Restated Agreement by executing a second amended and restated limited liability company agreement for the LLC dated September 6, 2013 (the “Second Restated
Agreement”) in connection with Celgene’s investment in the LLC and acquisition of Series B Units. 
 E. The members of the LLC
amended and restated the Second Restated Agreement by executing a third amended and restated limited liability company agreement for the LLC dated December 3, 2013 (the “Third Restated Agreement”) in connection with the
creation of “profits interests” to be issued to certain service providers for compensatory purposes. 
 F. NantWorks and
BlackBerry Corporation, a Delaware corporation (“BlackBerry”), amended and restated the Third Restated Agreement by executing a fourth amended and restated limited liability company agreement for the LLC dated March 28, 2014
(the “Fourth Restated Agreement”) in connection with BlackBerry’s investment in the LLC and acquisition of Series D Units of the LLC (the “Series D Units”). 

G. NantWorks and NHealth Holdings, Inc., a Delaware corporation (“NHealth”), amended and restated the Fourth Restated
Agreement by executing a fifth amended and restated limited liability company agreement for the LLC dated May 1, 2014 (the “Fifth Restated Agreement”) in connection with NHealth’s investment in the LLC and acquisition of
Series E Units of the LLC (the “Series E Units”). 
 H. NantWorks and KHealth Holdings, Inc., a Delaware corporation
(“KHealth”), amended and restated the Fifth Restated Agreement by executing a sixth amended and restated limited liability company agreement for the LLC dated June 20, 2014 (the “Sixth Restated Agreement”) in
connection with KHealth’s investment in the LLC and acquisition of Series F Units of the LLC (the “Series F Units”). 

  
 - 1 - 

 I. NantWorks and Blackstone Healthcare Partners II (AIV) L.L.C., a Delaware limited liability
company (together with its Permitted Transferees, “Blackstone”), amended and restated the Sixth Restated Agreement by executing a seventh amended and restated limited liability company agreement for the LLC dated July 9, 2014
(the “Seventh Restated Agreement”) in connection with Blackstone’s investment in the LLC and acquisition of Series A Units of the LLC (the “Series A Units”). 

J. NantWorks and Allscripts Healthcare Solutions, Inc., a Delaware corporation (“Allscripts”), amended and restated the
Seventh Restated Agreement by executing the eighth amended and restated limited liability agreement for the LLC dated June 26, 2015 (the “Eighth Restated Agreement”) in connection with Allscripts’ investment in the LLC and
acquisition of Series G Units of the LLC (the “Series G Units”). 
 K. NantWorks and Highmark Ventures, Inc., Independence
Blue Cross, LLC and Horizon Healthcare Services, Inc. (each, a “3BE Member” and together, the “3BE Members”), amended and restated the Eighth Restated Agreement by executing the ninth amended and restated limited
liability agreement for the LLC dated January 1, 2016 (the “Ninth Restated Agreement”) in connection with the LLC’s acquisition of NaviNet, Inc. and such 3BE Members’ investment in the LLC. 

L. Pursuant to Section 8.7.2 of the Ninth Restated Agreement, NantWorks has the right to cause the Company to convert the form of its
organization to a corporation (the “Conversion”) and NantWorks has determined it is in the best interest of the Company to effectuate the Conversion at this time. 

M. Pursuant to Section 8.7.3 of the Ninth Restated Agreement, in connection with the Conversion, the rights and obligations of the
Members (as defined in the Ninth Restated Agreement) in the new form of entity created in the Conversion shall be substantively the same as the rights and obligations of the Ninth Restated Agreement, and therefore, in connection with the Conversion
and the resulting termination of the Ninth LLC Agreement, NantWorks is entering into this Agreement to memorialize the rights and obligations of the Members. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Capitalized terms used herein without definition shall have the meanings given to them in Appendix 1 attached hereto and made
a part hereof. 
 ARTICLE 2 

ANTI-DILUTION AND PREEMPTIVE RIGHTS 

2.1 Anti-Dilution. 
 2.1.1 The
“Former Series B Price,” “Former Series D Price,” “Former Series E Price” and “Former Series F Price” initially shall be $[●], and shall be subject to adjustment as set forth in this Section 2.1. If
prior to a Qualified IPO, there shall be an adjustment to the Former Series B Price pursuant to the provisions in this Section 2.1, then, in connection with each such adjustment, the number of shares of Common Stock held by the Former
Series B Members shall be automatically adjusted (with the impact 

  
 - 2 - 

 
of such adjustment allocated pro rata among the Former Series B Members based on the number of shares of Common Stock held by the Former Series B Members as of the date of this Agreement)
such that the number of shares of Common Stock held by the Former Series B Members in the aggregate immediately following such adjustment shall be equal to $50.0 million divided by the newly effective Former Series B Price. If prior to a
Qualified IPO, there shall be an adjustment to the Former Series D Price pursuant to the provisions in this Section 2.1, then, in connection with each such adjustment, the number of shares of Common Stock held by the Former Series D Member
shall be automatically adjusted (with the impact of such adjustment allocated pro rata among the Former Series D Member based on the number of shares of Common Stock held by the Former Series D Member as of the date of this Agreement) such that
the number of shares of Common Stock held by the Former Series D Member in the aggregate immediately following such adjustment shall be equal to $10.0 million divided by the newly effective Former Series D Price. If prior to or in
connection with a Qualified IPO, there shall be an adjustment to the Former Series E Price pursuant to the provisions in this Section 2.1, then, in connection with each such adjustment, the number of shares of Common Stock held by the
Former Series E Member shall be automatically adjusted (with the impact of such adjustment allocated pro rata among the Former Series E Member based on the number of shares of Common Stock held by the Former Series E Members as of the
date of this Agreement) such that the number of shares of Common Stock held by the Former Series E Member in the aggregate immediately following such adjustment shall be equal to $100.0 million divided by the newly effective Former Series
E Price. If prior to or in connection with a Qualified IPO, there shall be an adjustment to the Former Series F Price pursuant to the provisions in this Section 2.1, then, in connection with each such adjustment, the number of shares of
Common Stock held by the Former Series F Member shall be automatically adjusted (with the impact of such adjustment allocated pro rata among the Former Series F Member based on the number of shares of Common Stock held by the Former
Series F Member as of the date of this Agreement) such that the number of shares of Common Stock held by the Former Series F Member in the aggregate immediately following such adjustment shall be equal to $150.0 million divided by the
newly effective Former Series F Price. 
 2.1.2 If after the Effective Date, the Company shall issue any Additional Shares without
consideration or for a consideration per share less than the Former Series B Price in effect immediately prior to the issuance of such Additional Shares, the Former Series B Price in effect immediately prior to each such issuance shall forthwith
(except as otherwise provided in this Section 2.1) be adjusted to a price determined by multiplying such Former Series B Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding (and deemed issued
pursuant to Section 2.1.6 below) immediately prior to such issuance plus the number of Additional Shares that the aggregate consideration received by the Company for such issuance would purchase at such Former Series B Price; and the
denominator of which shall be the number of shares of Common Stock outstanding (and deemed issued pursuant to Section 2.1.6 below) plus the number of such Additional Shares. If after the Effective Date, the Company shall issue any Additional
Shares without consideration or for a consideration per share less than the Former Series D Price in effect immediately prior to the issuance of such Additional Shares, the Former Series D Price in effect immediately prior to each such issuance
shall forthwith (except as otherwise provided in this Section 2.1) be adjusted to a price determined by multiplying such Former Series D Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding
(and deemed issued pursuant to Section 2.1.6 below) immediately prior to such issuance plus the number of Additional Shares that the aggregate consideration received by the Company for such issuance would purchase at such Former Series D Price;
and the denominator of which shall be the number of shares of Common Stock outstanding (and deemed issued pursuant to Section 2.1.6 below) plus the number of such Additional Shares. If after the Effective Date (including in connection with an
IPO), the Company shall issue any Additional Shares without consideration or for a consideration per share less than the Former Series E Price in effect immediately prior to the issuance of such Additional Shares, the Former Series E Price in effect
immediately prior to 

  
 - 3 - 

 
each such issuance shall forthwith (except as otherwise provided in this Section 2.1) be adjusted to a price determined by multiplying such Former Series E Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding (and deemed issued pursuant to Section 2.1.6 below) immediately prior to such issuance plus the number of Additional Shares that the aggregate consideration received
by the Company for such issuance would purchase at such Former Series E Price; and the denominator of which shall be the number of shares of Common Stock outstanding (and deemed issued pursuant to Section 2.1.6 below) plus the number of such
Additional Shares. If after the Effective Date (including in connection with an IPO), the Company shall issue any Additional Shares without consideration or for a consideration per share less than the Former Series F Price in effect immediately
prior to the issuance of such Additional Shares, the Former Series F Price in effect immediately prior to each such issuance shall forthwith (except as otherwise provided in this Section 2.1.6) be adjusted to a price determined by
multiplying such Former Series F Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding (and deemed issued pursuant to Section 2.1.6 below) immediately prior to such issuance plus the number
of Additional Shares that the aggregate consideration received by the Company for such issuance would purchase at such Former Series F Price; and the denominator of which shall be the number of shares of Common Stock outstanding (and deemed
issued pursuant to Section 2.1.6 below) plus the number of such Additional Shares. 
 2.1.3 No adjustment of the Former Series B Price,
Former Series D Price, Former Series E Price or Former Series F Price shall be made in an amount less than one cent ($0.01) per share, provided that any adjustments that are not required to be made by reason of this sentence shall
be carried forward and shall be either taken into account in any subsequent adjustment made prior to three (3) years from the date of the event giving rise to the adjustment being carried forward, or shall be made at the end of three
(3) years from the date of the event giving rise to the adjustment being carried forward. Except as otherwise set forth herein, no adjustment of such Former Series B Price, Former Series D Price, Former Series E Price or Former Series
F Price pursuant to this Section 2.1 shall have the effect of increasing the Former Series B Price above the Former Series B Price in effect immediately prior to such adjustment, the Former Series D Price above the Former Series D
Price in effect immediately prior to such adjustment, the Former Series E Price above the Former Series E Price in effect immediately prior to such adjustment or the Former Series F Price above the Former Series F Price in effect
immediately prior to such adjustment. 
 2.1.4 In the case of the issuance of Additional Shares for cash, the consideration shall be deemed
to be the amount of cash paid therefor before deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by the Company for any underwriting or otherwise in connection with the issuance and sale thereof. 

2.1.5 In the case of the issuance of the Additional Shares to any Affiliate of NantWorks for a consideration in whole or in part other than
cash, the consideration other than cash shall be deemed to be the fair market value thereof as mutually agreed to by the Board, Verizon, NHealth and KHealth. In the case of the issuance of the Additional Shares to any Person other than an Affiliate
of NantWorks for a consideration in whole or in part other than cash, the consideration other than cash shall be deemed to be the fair market value thereof as reasonably determined in good faith by the Board. 

  
 - 4 - 

 2.1.6 In the case of the issuance of Convertible Securities or options to purchase or rights to
subscribe for such Convertible Securities, the following provisions shall apply for all purposes of this Section 2.1: 
 (a) The
aggregate maximum number of shares of Common Stock deliverable upon exercise (assuming the satisfaction of any conditions to exercisability, including, without limitation, the passage of time) shall be deemed to have been issued at the time such
options or rights were issued and for a consideration equal to the consideration (determined in the manner provided in Sections 2.1.4 and 2.1.5 above), if any, received by the Company upon the issuance of such options or rights plus the minimum
exercise price provided in such options or rights for the shares of Common Stock covered thereby. 
 (b) The aggregate maximum number of
shares of Common Stock deliverable upon conversion of, or in exchange (assuming the satisfaction of any conditions to convertibility or exchangeability, including, without limitation, the passage of time) for any such Convertible Securities or upon
the exercise of options to purchase or rights to subscribe for such Convertible Securities and subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options or rights were
issued and for a consideration equal to the consideration, if any, received by the Company for any such securities and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum
additional consideration, if any, to be received by the Company upon the conversion or exchange of such securities or the exercise of any related options or rights (the consideration in each case to be determined in the manner provided in
Sections 2.1.4 and 2.1.5 above). 
 (c) In the event of any change in the number of shares of Common Stock deliverable or in the
consideration payable to the Company upon exercise of such options or rights or upon conversion of or in exchange for such Convertible Securities, including, but not limited to, a change resulting from the antidilution provisions thereof, the Former
Series B Price, the Former Series D Price, the Former Series E Price and the Former Series F Price (in each case to the extent in any way affected by or computed using such options, rights or securities), and the number of additional
shares of Common Stock deemed to have been issued pursuant to Section 2.1.1, shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of shares of Common Stock or any payment of such
consideration upon the exercise of any such options or rights or the conversion or exchange of such securities. 
 (d) Upon the expiration
of any such options or rights, the termination of any such right to convert or exchange or the expiration of any options or rights related to such Convertible Securities, the Former Series B Price, the Former Series D Price, the Former
Series E Price and the Former Series F Price (in each case to the extent in any way affected by or computed using such options, rights or securities or options or rights related to such securities) and the number of additional shares of Common
Stock deemed to have been issued pursuant to Section 2.1.1 shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and Convertible Securities that remain in effect) actually issued upon the exercise of such
options or rights, upon the conversion or exchange of such securities or upon the exercise of the options or rights related to such securities. 

(e) The number of shares of Common Stock deemed issued and the consideration deemed paid therefor pursuant to Sections 2.1.6(a) and
2.1.6(b), and the number of additional shares of Common Stock deemed to have been issued pursuant to Section 2.1.1, shall be appropriately adjusted to reflect any change, termination or expiration of the type described in either
Section 2.1.6(c) and 2.1.6(d). 
 (f) “Additional Shares” shall mean any shares of Common Stock issued (or deemed to
have been issued pursuant to this Section 2.1.6) by the Company other than: 
 (i) Common Stock issued pursuant to stock splits, stock
dividends, reclassifications and the like; 

  
 - 5 - 

 (ii) Common Stock or Convertible Securities issued or deemed issued to employees, consultants or
contractors of the Company for compensatory purposes; 
 (iii) Common Stock issued or issuable in connection with any transaction where
such Common Stock is excepted from the definition of Additional Shares with the approval or consent of Verizon, NHealth and KHealth; or 

(iv) Common Stock issued or issuable to the selling parties in a bona fide business acquisition by the Company or any of its subsidiaries,
whether by merger, consolidation, sale of assets, sale or exchange of equity or otherwise, each as approved by the Board. 
 (g) Other than
in connection with a Qualified IPO or with the consent of NantWorks, Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and each 3BE Member, the Company shall not at any time split or subdivide the outstanding shares of Common
Stock, decrease the number of shares of Common Stock outstanding by a combination of the outstanding shares of Common Stock, or make a dividend to holders of Common Stock or Convertible Securities, or entitling such holders to receive directly or
indirectly, additional shares of Common Stock in respect of their shares of Common Stock. 
 2.1.7 The Company will not, by amendment of
this Agreement or through any reorganization, recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Section 2.1 and in the taking of all such action as may be necessary or appropriate in
order to protect the rights of the stockholders against impairment. 
 2.1.8 Upon the occurrence of each adjustment of the Former Series B
Price, the Former Series D Price, the Former Series E Price or the Former Series F Price, the Company, at its expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to
each holder of shares of Common Stock, together with a certificate setting forth such adjustment and showing in reasonable detail the facts upon which such adjustment is based. 

2.2 Preemptive Rights. The Company hereby grants preemptive rights to each of NantWorks, Verizon, Celgene, BlackBerry, NHealth,
KHealth, Blackstone and Allscripts (together, the “Preemptive Right Holders”) as provided in this Section 2.2. If the Company proposes to issue additional shares of Common Stock, Preferred Stock or Convertible Securities (such
shares of Common Stock, Preferred Stock or Convertible Securities, “Subsequent Equity”), then the Company shall deliver to each Preemptive Right Holder a written notice (the “Preemptive Notice”) of such proposed
issuance at least fifteen (15) days prior to the date of the issuance (the “Subscription Period”). Each Preemptive Right Holder shall have the option, exercisable at any time within the period of thirty (30) days after
delivery of the Preemptive Notice (the “Preemptive Acceptance Period”), by delivering a written notice to the Company (a “Subscription Acceptance”) and on the same terms (on a per share basis) as those proposed for
the issuance of such Subsequent Equity, to subscribe for (x) up to its pro rata share of any such Subsequent Equity and (y) any such Subsequent Equity not subscribed for by the other Preemptive Right Holders, as specified in the
subscribing holder’s Subscription Acceptance provided that, in the event that any such Subsequent Equity is Preferred Stock, a Preemptive Right Holder’s respective pro rata share of such Subsequent Equity, for purposes of this
Section 2.2, shall be a percentage equal to the greater of (a) such Preemptive Right Holder’s pro rata share of Common Stock and Convertible Securities and (b) such Preemptive Right Holder’s pro rata share of such Preferred
Stock. Notwithstanding anything herein to the contrary, the Company may close the issuance of Subsequent Equity, in whole or in part, prior to the 

  
 - 6 - 

 
expiration of the Preemptive Acceptance Period provided above as long as each Preemptive Right Holder is given the Preemptive Acceptance Period to elect to purchase its pro rata share of the
applicable Subsequent Equity. Any Subsequent Equity that is not purchased by the Preemptive Rights Holders may be sold by the Company, but only on terms and conditions not more favorable to the purchaser than those set forth in the Preemptive
Notice, at any time within 90 days following the termination of the Preemptive Acceptance Period, but may not be sold to any Person on terms and conditions, including price, that are more favorable to the purchaser than those set forth in the
Preemptive Notice or after such 90-day period, in each case without renewed compliance with this Section 2.2. The preemptive rights granted pursuant to this Section 2.2 shall not be applicable to:

 (a) the issuance of shares of Common Stock in connection with a conversion under Section 8.7.2 of the Ninth Restated Agreement;

 (b) the issuance of shares of Common Stock as a dividend or distribution to all or substantially all holders of Common Stock, or a
subdivision or combination of shares of Common Stock or a reclassification of (or similar action with respect to) shares of Common Stock into a greater or lesser number of shares of Common Stock; 

(c) the issuance of Common Stock or Convertible Securities to employees, consultants and contractors of the Company for compensatory
purposes; 
 (d) the issuance of shares of Common Stock upon the exercise or exchange of Convertible Securities; 

(e) the issuance of shares of Common Stock in the Company in a Qualified IPO; and 

(f) the issuance of shares of Common Stock to the selling parties in a bona fide business acquisition by the Company or any of its
subsidiaries, whether by merger, consolidation, sale of assets, sale or exchange of equity or otherwise, each as approved by the Board. 

2.3 Other Activities. The Holders acknowledge and agree that, subject to the terms of this Agreement and any employment or consulting
agreement entered into between the Company and a Holder or its Affiliates or its or their respective officers, directors, shareholders, partners, members, managers, agents or employees: 

2.3.1 Each Holder and its Affiliates and its and their respective officers, directors, shareholders, partners, members, managers, agents and
employees may engage or invest in, independently or with others, any business activity of any type or description (including activities that might be the same as or similar to the business of the Company or any of its controlled Affiliates), and
neither the Company nor any Holder shall have any right in or to such other ventures or activities or to the income or proceeds derived therefrom; 

2.3.2 No Holder nor any of its Affiliates nor any of its or their respective officers, directors, shareholders, partners, members, managers,
agents or employees shall be obligated to present any investment opportunity or prospective economic advantage to the Company, even if the opportunity is of the character that, if presented to the Company, could be taken by the Company, and the
doctrine of corporate opportunity or any analogous doctrine shall not apply to any of the Company’s Holders or Affiliates or their respective officers, directors, shareholders, partners, members, managers, agents or employees; and 

  
 - 7 - 

 2.3.3 Each Holder and its Affiliates and its and their respective officers, directors,
shareholders, partners, members, managers, agents and employees shall have the right to hold any investment opportunity or prospective economic advantage for its own account or to recommend such opportunity to Persons other than the Company. 

2.4 Transactions With The Company. Subject to any limitations set forth in this Agreement, including without limitation Sections 3.2
and 3.7, and with the prior approval of the Board, each Holder and its Affiliates and its and their respective officers, directors, shareholders, partners, members, managers, agents and employees may lend money to and transact other business with
the Company. Subject to other applicable law, such Holder or such other Person shall have the same rights and obligations with respect thereto as a Person who is not a Holder. 

2.5 Issuance of Shares. The Company has reserved an aggregate of 63,750,000 shares for issuance by the Company pursuant to its equity
plans (a “Plan”). The shares of Common Stock shall only be issued to employees, consultants and contractors of the Company and its subsidiaries (who are not shareholders, members, partners, managers, officers, employees, consultants
or contractors of NantWorks or its Affiliates (other than the Company)) in consideration for bona fide services provided to the Company or such subsidiary, and shall otherwise be upon such terms and conditions as the Board shall determine, in its
reasonable discretion, to be in the best interests of the Company. Subject to the foregoing, the Board is authorized to issue any shares of Common Stock pursuant to a Plan and on such terms and conditions as in its reasonable discretion it deems
appropriate, which terms and conditions shall include customary vesting schedules and other terms and conditions applicable to such employees, consultants and contractors. Each issuance of shares of Common Stock pursuant to a Plan shall be evidenced
by a writing signed by an officer of the Company pursuant to the authorization of the Board. 
 2.6 Certain Covenants. In the event
that the Company determines to effectuate a Liquidity Event prior to a Qualified IPO or a Liquidity Event occurs prior to a Qualified IPO, the Company, NantWorks and the Holders agree to amend the certificate of incorporation of the Company
effectuated at the Conversion so that the governance, transfer restrictions, anti-dilution, liquidity and preference rights and other provisions therein with respect to the Holders correspond in the aggregate in all substantive respects with the
provisions contained in the Ninth Restated Agreement; provided that prior to the earlier of a Qualified IPO or such amendments to the certificate of incorporation of the Company, the Company will not take any actions that would have resulted in
Holders receiving rights or benefits pursuant the Ninth Restated Agreement that such Holders no longer have pursuant to this Agreement. 

ARTICLE 3 
 MANAGEMENT
AND CONTROL OF THE COMPANY 
 3.1 Election of Board Members. 

3.1.1 Number, Appointment, Removal and Resignation; Observers. 

(a) The Board shall initially consist of seven (7) directors (each, a “Director”). 

(b) Holders of a majority of the shares of Common Stock that were issued at the time of the Conversion to the Former Series A Members, voting
as a separate class (the “Former Series A Majority”), shall be entitled to appoint six (6) Directors (each, a “Former Series A Director”) and Verizon shall be entitled to appoint one Director (the
“Verizon Director”). Each Director shall be entitled to one vote for any action taken by the Board; except that if the Former Series A Majority has 

  
 - 8 - 

 
appointed fewer Directors than it is entitled to appoint under this Agreement, then for any action taken by the Board, the Former Series A Director(s) shall be entitled to cast an aggregate
number of votes equal to the number of Directors that the Former Series A Majority is entitled to appoint (i.e., six). For example, if the Former Series A Majority only appoints two (2) Directors, then those two Former Series A Directors
shall be entitled to an aggregate of six (6) votes for any action taken by the Board. The Verizon Director shall be entitled to serve on each committee of the Board. 

(c) Each of the Former Series A Majority and Verizon shall notify the Company of the name, business address and business telephone and
facsimile numbers of each Director(s) designated by such party. Each appointment by the Former Series A Majority or Verizon, as applicable, of a Director shall remain in effect until the party making such appointment notifies the Company of a change
in such appointment. Each of the Former Series A Majority or Verizon shall promptly notify the Company of any change in such party’s contact information. 

(d) Each Director may be removed as such, with or without cause, and his or her successor may be designated by the Former Series A Majority
or Verizon, as applicable and as entitled to designate such Director as set forth in this Section 3.1.1; provided that the Verizon Director may only be removed by Verizon and the Former Series A Director may only be removed by the Former
Series A Majority. 
 (e) Any Director may resign at any time by giving written notice to the Company and remaining Directors without
prejudice to the rights, if any, of the Company under any contract to which the resigning Director is a party. The resignation of any Director shall take effect upon receipt of that notice or at such later time as shall be specified in the notice;
and, unless otherwise specified in the notice, the acceptance of the resignation shall not be necessary to make it effective. If a vacancy occurs on the Board, the vacancy shall be filled by the designation of the Former Series A Majority or
Verizon, as applicable and as entitled to designate such Director as set forth in this Section 3.1.1. 
 (f) The resignation or
removal of a Director shall not invalidate any act of such Board member taken before the giving of such written notice of the removal or resignation of such Director. 

(g) Each of Verizon (in lieu of appointing the Verizon Director), Celgene, BlackBerry, NHealth, KHealth, Allscripts and the 3BE Members
(acting collectively to appoint a single representative) shall have the right to designate a representative (the “Board Observer”) to attend, strictly as an observer, all meetings of the Board (or committees thereof) (it being
agreed and acknowledged that the Board Observer will have no power or authority to act or vote at such meetings). The Company shall provide the Board Observer with notice of all meetings of, and all information delivered to, the members of the Board
and any committee thereof, including all consents, minutes and other materials, financial or otherwise, which the Company provides to the Board; provided, that Company reserves the right to withhold any information and to exclude such Board
Observer from any meeting or any portion thereof if access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets or
particularly sensitive confidential information relating to a telecommunications service provider with whom Verizon then competes in the United States. Such Board Observer shall agree to hold in confidence all such information provided.
Notwithstanding anything to the contrary in this Agreement, such Board Observer may use any learning, skills, ideas, concepts, techniques, know-how, and information retained in intangible form in the unaided memory of such Board Observer
(collectively, “Residual Information”) for any purpose; provided that such learning, skills, ideas, concepts, techniques, 

  
 - 9 - 

 
know-how, and information was not intentionally memorized for the purpose of retaining and subsequently using them outside of the purposes contemplated by this Agreement. For the avoidance of
doubt, nothing contained in the preceding sentence (i) gives a Board Observer the right to publish or otherwise disclose or use the tangible source of any Residual Information for any purpose other than as provided for in this Agreement or
(ii) grants a license to any intellectual property. 
 (h) The Company shall reimburse each Director (and the Board Observers if
applicable) for all reasonable and documented out-of-pocket expenses incurred in connection with their attendance at meetings of the Board or Board committee meetings or any other activities (e.g., meetings, trade shows) as requested and
approved in advance by the Company. 
 3.2 Verizon Approval Rights. So long as Verizon holds at least the Minimum Verizon Ownership
Amount, the Company shall not, and shall not permit any wholly-owned subsidiary to, or vote its equity in any non-wholly owned subsidiary in favor of or cause any designated director serving on the board of directors of any such non-wholly owned
subsidiary to, without the prior written consent of Verizon: 
 3.2.1 Engage in any principal business other than the Nant Health Business;

 3.2.2 Incur indebtedness, including any guarantees of any indebtedness of any Person, in excess of $25.0 million individually or in the
aggregate; 
 3.2.3 Make any investment in or acquisition of Persons, businesses or assets that are outside of the scope of operation and
business purpose of the Company (other than any such investments or acquisitions with a purchase price of less than $10.0 million individually and in the aggregate in any calendar year); or 

3.2.4 Enter into any material transaction with Affiliates, including NantWorks and any subsidiary or Affiliate thereof, except (i) in the
case of a transaction with consideration or expenditures of $5.0 million or less, the Board has determined in good faith that such transaction is fair to the Company or (ii) in the case of a transaction with consideration or expenditures
in excess of $5.0 million, the Board demonstrates to the reasonable satisfaction of Verizon that such transaction is on arms’ length terms. 

3.3 Notification Rights. Notwithstanding anything to the contrary in this Agreement, so long as Verizon holds at least the Minimum
Verizon Ownership Amount, Celgene holds at least the Minimum Celgene Ownership Amount, BlackBerry holds at least the Minimum Blackberry Ownership Amount, NHealth holds at least the Minimum NHealth Ownership Amount, KHealth holds at least the Minimum
KHealth Ownership Amount, Blackstone holds at least the Minimum Blackstone Ownership Amount, Allscripts holds at least the Minimum Allscripts Ownership Amount or the 3BE Members hold at least the Minimum 3BE Holdings’ Ownership Amount, the
Company shall notify Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and the 3BE Members, respectively, within ten (10) business days after the Company: 

3.3.1 Approves an annual budget (and makes any material amendment to such annual budget or the business plan); 

3.3.2 Makes or incurs, or commits to make or incur, any material capital expenditure not expressly contemplated by the annual budget; 

  
 - 10 - 

 3.3.3 Makes investments in or acquisitions or divestitures of Persons, businesses or assets with
a value of more than $10.0 million; 
 3.3.4 Enters into any agreement with respect to a Liquidity Event, grants an exclusive license to all
or substantially all of the Company’s intellectual property or the Board appoints a Person to wind-up the affairs of the Company; or 

3.3.5 Without limiting Section 6.13, materially amends this Agreement or the Company Charter. 

3.4 Celgene Approval Rights. So long as Celgene holds at least the Minimum Celegene Ownership Amount, the Company shall not, and shall
not permit any wholly-owned subsidiary to, or vote its equity in any non-wholly owned subsidiary in favor of or cause any designated director serving on the board of directors of any such non-wholly owned subsidiary to, directly, or indirectly, by
amendment, merger, recapitalization, sale, consolidation or otherwise, without the prior written consent of Celgene Purchase or redeem any shares of Common Stock or Preferred Stock, other than (a) in connection with a Liquidity Event or
Qualified IPO, (b) in connection with the repurchase of Common Stock issued to or held by employees, consultants or contractors of the Company at a price not greater than the then current fair market value for such Common Stock upon termination
of their employment or services pursuant to agreements providing for the right of said repurchase and (c) repurchases determined by the Board in good faith to be in the best interests of the Company in an amount not to exceed $5.0 million in
any 12 month period. 
 3.5 NHealth Approval Rights. So long as NHealth holds at least the Minimum NHealth Ownership Amount, the
Company shall not, and shall not permit any wholly-owned subsidiary to, or vote its equity in any non-wholly owned subsidiary in favor of or cause any designated director serving on the board of directors of any such non-wholly owned subsidiary to,
directly, or indirectly, by amendment, merger, recapitalization, sale, consolidation or otherwise, without the prior written consent of NHealth: 

3.5.1 Engage in any principal business other than the Nant Health Business; 

3.5.2 Incur indebtedness, including any guarantees of any indebtedness of any Person, in excess of $25.0 million individually or in the
aggregate; 
 3.5.3 Make any investment in or acquisition of Persons, businesses or assets that are outside of the scope of operation and
business purpose of the Company (other than any such investments or acquisitions with a purchase price of less than $10.0 million individually and in the aggregate in any calendar year); 

3.5.4 Enter into any material transaction with Affiliates, including NantWorks and any subsidiary or Affiliate thereof, except (i) in the
case of a transaction with consideration or expenditures of $5.0 million or less, the Board has determined in good faith that such transaction is fair to the Company or (ii) in the case of a transaction with consideration or expenditures
in excess of $5.0 million, the Board demonstrates to the reasonable satisfaction of NHealth that such transaction is on arms’ length terms; or 

3.5.5 Purchase or redeem any shares of Common Stock or Preferred Stock, other than (a) in connection with a Liquidity Event or Qualified
IPO, (b) in connection with the repurchase of Common Stock issued to or held by employees, consultants or contractors of the Company at a price not greater than the then current fair market value for such Common Stock upon termination of their
employment or services pursuant to agreements providing for the right of said repurchase and (c) repurchases determined by the Board in good faith to be in the best interests of the Company in an amount not to exceed $5.0 million in any 12
month period. 

  
 - 11 - 

 Notwithstanding any other provision of this Agreement to the contrary, if any Person purchases any shares of
Common Stock or Preferred Stock such that the aggregate purchase price paid by such Person for all of its shares of Common Stock or Preferred Stock is equal to or less than the aggregate purchase price paid by NHealth for all of its equity interests
in the Company, and such Person receives any rights, preferences or privileges in respect of its shares of Common Stock that NHealth does not enjoy in respect of its Common Stock or Preferred Stock, then NHealth shall automatically, without any
further action of the Board or any Holder, be entitled to such rights, privileges or preferences in respect of its Common Stock. 
 3.6
KHealth Approval Rights. So long as KHealth holds at least the Minimum KHealth Ownership Amount, the Company shall not, and shall not permit any wholly-owned subsidiary to, or vote its equity in any non-wholly owned subsidiary in favor of or
cause any designated director serving on the board of directors of any such non-wholly owned subsidiary to, directly, or indirectly, by amendment, merger, recapitalization, sale, consolidation or otherwise, without the prior written consent of
KHealth: 
 3.6.1 Engage in any principal business other than the Nant Health Business; 

3.6.2 Incur indebtedness, including any guarantees of any indebtedness of any Person, in excess of $25.0 million individually or in the
aggregate; 
 3.6.3 Make any investment in or acquisition of Persons, businesses or assets that are outside of the scope of operation and
business purpose of the Company (other than any such investments or acquisitions with a purchase price of less than $10.0 million individually and in the aggregate in any calendar year); 

3.6.4 Enter into any material transaction with Affiliates, including NantWorks and any subsidiary or Affiliate thereof, except (i) in the
case of a transaction with consideration or expenditures of $5.0 million or less, the Board has determined in good faith that such transaction is fair to the Company or (ii) in the case of a transaction with consideration or expenditures
in excess of $5.0 million, the Board demonstrates to the reasonable satisfaction of KHealth that such transaction is on arms’ length terms; or 

3.6.5 Purchase or redeem any shares of Common Stock or Preferred Stock, other than (a) in connection with a Liquidity Event or Qualified
IPO, (b) in connection with the repurchase of Common Stock issued to or held by employees, consultants or contractors of the Company at a price not greater than the then current fair market value for such Common Stock upon termination of their
employment or services pursuant to agreements providing for the right of said repurchase and (c) repurchases determined by the Board in good faith to be in the best interests of the Company in an amount not to exceed $5.0 million in any 12
month period. 
 Notwithstanding any other provision of this Agreement to the contrary, if any Person purchases any shares of Common Stock or Preferred
Stock such that the aggregate purchase price paid by such Person for all of its Common Stock or Preferred Stock is equal to or less than the aggregate purchase price paid by KHealth for all of its equity interests in the Company, and such Person
receives any rights, preferences or privileges in respect of its shares of Common Stock or Preferred Stock that KHealth does not enjoy in respect of its Common Stock, then KHealth shall automatically, without any further action of the Board or any
Holder, be entitled to such rights, preferences or privileges in respect of its Common Stock.  

  
 - 12 - 

 3.7 Allscripts Approval Rights. So long as Allscripts holds at least the Minimum
Allscripts Ownership Amount, the Company shall not, and shall not permit any wholly-owned subsidiary to, or vote its equity in any non-wholly owned subsidiary in favor of or cause any designated director serving on the board of directors of any such
non-wholly owned subsidiary to, directly, or indirectly, by amendment, merger, recapitalization, sale, consolidation or otherwise, without the prior written consent of Allscripts: 

3.7.1 Engage in any principal business other than the Nant Health Business; 

3.7.2 Incur indebtedness, including any guarantees of any indebtedness of any Person, in excess of $25.0 million individually or in the
aggregate; 
 3.7.3 Make any investment in or acquisition of Persons, businesses or assets that are outside of the scope of operation and
business purpose of the Company (other than any such investments or acquisitions with a purchase price of less than $10.0 million individually and in the aggregate in any calendar year); 

3.7.4 Enter into any material transaction with Affiliates (which material transaction includes, for the avoidance of doubt, entering into any
agreement or any amendment, modification or waiver thereof), including NantWorks and any subsidiary or Affiliate thereof, except (i) in the case of a transaction with consideration or expenditures of $5.0 million or less, the Board has
determined in good faith that such transaction is fair to the Company or (ii) in the case of a transaction with consideration or expenditures in excess of $5.0 million, the Board demonstrates to the reasonable satisfaction of Allscripts that
such transaction is on arms’ length terms; or 
 3.7.5 Purchase or redeem any shares of Common Stock or Preferred Stock, other than
(a) in connection with a Liquidity Event or Qualified IPO, (b) in connection with the repurchase of Common Stock issued to or held by employees, consultants or contractors of the Company at a price not greater than the then current fair
market value for such Common Stock upon termination of their employment or services pursuant to agreements providing for the right of said repurchase and (c) repurchases determined by the Board in good faith to be in the best interests of the
Company in an amount not to exceed $5.0 million in any 12 month period. 
 Notwithstanding any other provision of this Agreement to the contrary, if any
Person purchases any class or series of shares of Common Stock or Preferred Stock such that the aggregate purchase price paid by such Person for all of its shares of Common Stock or Preferred Stock is equal to or less than the aggregate purchase
price paid by Allscripts for all of its equity interests in the Company, and such Person receives any rights, preferences or privileges in respect of its Common Stock or Preferred Stock that Allscripts does not enjoy in respect of its Common Stock,
then Allscripts shall automatically, without any further action of the Board or any Holder, be entitled to such rights, preferences or privileges in respect of its Common Stock.  

3.8 Indemnification. 

3.8.1 For the purposes of this Section 3.8, (i) “proceeding” means any threatened, pending or completed claim,
demand, action or proceeding, whether civil, criminal, administrative, legislative or investigative; and (ii) “expenses” includes without limitation attorneys’ fees and any expenses of establishing a right to
indemnification under this Section 3.8. 

  
 - 13 - 

 3.8.2 Except as expressly provided in this Section 3.8, the Company shall, to the fullest
and broadest extent permitted by the laws of the State of Delaware, indemnify and hold harmless any Indemnifiable Person against all losses, Damages, liabilities or expenses, of any kind or nature, incurred by it while acting (or omitting to act) in
good faith on behalf of the Company or otherwise relating to the Company. Any indemnity under this Section 3.8.2 shall be provided out of and to the extent of the Company’s assets only, and no Holder shall have any personal liability with
respect to such indemnity. Without limiting the generality of the foregoing, but subject thereto, the Company hereby agrees to indemnify each Indemnifiable Person, and to save and hold him, her or it harmless, from and in respect of (i) all
fees, costs and expenses incurred in connection with or resulting from any demand, claim, action or proceeding against such Indemnifiable Person or the Company which arises out of or in any way relates to the Company or its properties, business or
affairs, and (ii) all such demands, claims, actions and proceedings and any losses or Damages resulting therefrom, including judgments, fines and amounts paid in settlement or compromise of any such demand, claim, action or proceeding. No
indemnity in this Section 3.10 shall extend to conduct by an Indemnifiable Person with respect to the Company’s business which is determined by a court of competent jurisdiction to have not been taken with a good faith belief that such
action was in or not opposed to the best interests of the Company. 
 3.8.3 The Company shall pay the expenses incurred by any Indemnifiable
Person in connection with any proceedings in advance of the final disposition of such proceeding, upon receipt of an undertaking by such Indemnifiable Person to repay such payment if there shall be an adjudication or determination that such
Indemnifiable Person is not entitled to indemnification as a result of Section 3.8.2. The Board shall be authorized, on behalf of the Company, to enter into indemnity agreements from time to time with any Person entitled to be indemnified by
the Company hereunder, upon such terms and conditions as the Board deems appropriate in its business judgment. The indemnification and advancement of expenses provided by, or granted pursuant to, the provisions of this Section 3.8.3, shall not
be deemed exclusive of any other rights to which any Person seeking indemnification or advancement of expenses may be entitled under any agreement (approved by the Board) or otherwise, both as to action in such Person’s capacity as an agent of
the Company and as to action in another capacity while serving as an agent. 
 3.9 Insurance of Agents. The Company shall have the
power to purchase and maintain insurance on behalf of any Person who is or was a member of the Board, an officer of the Company, an employee or agent of the Company, against any liability asserted against such Person and incurred by such Person in
any such capacity, or arising out of such Person’s status as a member of the Board, officer of the Company, an employee or agent of the Company whether or not the Company would have the power to indemnify such Person against such liability
under the provisions of Section 3.8 or under applicable law. 
 ARTICLE 4 

TRANSFER OF SHARES 
 4.1
Transfers. Without the prior written consent of the board of directors of the Company (the “Board”), no Holder may directly or indirectly sell, assign, transfer, pledge, hypothecate or otherwise dispose of such Holder’s
shares of Common Stock, nor any part thereof, except as permitted in this Article 4. For the avoidance of doubt, the provisions of Section 4.5 shall apply whether or not the Board consents to such transfer. Except as set forth in this
Article 4, any act in violation of this Section 4.1 shall be voidable by the Company or any Holder. 
 4.2 Permitted
Transfers. Notwithstanding the restrictions set forth in Section 4.1, a Holder shall have the right to assign all or a portion of its Common Stock (by operation of law or otherwise) without the consent of the Board or the other Holders to
such Holders’ Permitted Transferees, but only if the transferee promptly notifies the Board and executes an instrument satisfactory to the Board accepting 

  
 - 14 - 

 
and adopting the terms and provisions of this agreement. If a Holder transfers any shares of its Common Stock to a Permitted Transferee pursuant to this Section 4.2, such Permitted
Transferee shall become a party to this Agreement as a Holder without the consent of the non-transferring Holders or the Board and with respect to a Permitted Transferee who acquires all of such Holder’s shares of Common Stock, all references
herein to the transferring Holder shall be deemed to be references to such Permitted Transferee. 
 The transfer of shares to a new Holder shall not result
in the release of the Holder who assigned the Common Stock from any liability that such assigning Holder may have incurred to the Company prior to such assignment. 

4.3 Right of First Refusal. Except as provided in Section 4.5, each time a Holder (other than NantWorks or any of its Permitted
Transferees) proposes to transfer, assign, convey, sell, encumber or in any way alienate all or any part of such Holder’s shares of Common Stock (or as required by operation of law or other involuntary transfer to do so) other than to a
Permitted Transferee in a transaction permitted by Section 4.2, such Holder (a “Restricted Selling Holder”) shall first offer such shares of Common Stock to NantWorks in accordance with the following provisions: 

4.3.1 The Restricted Selling Holder shall deliver a written notice to the Company and NantWorks stating (i) such Restricted Selling
Holder’s bona fide intention to transfer all or a part of its shares of Common Stock, (ii) the name and address of the proposed transferee, (iii) the number of shares of Common Stock to be transferred, (iv) the purchase price in
terms of payment for which the Restricted Selling Holder proposes to transfer such Common Stock and (v) any other material terms and conditions of such transfer. 

4.3.2 Within thirty (30) days after receipt of the notice described in Section 4.3.1 (or if the notice provides for the payment of
non-cash consideration, no later than thirty (30) days after determination of the fair market value thereof in accordance with the last sentence of Section 4.3.3), NantWorks shall notify the Company and the Restricted Selling Holder in
writing of its desire to purchase all of the shares of Common Stock being so transferred. The failure of NantWorks to submit a notice within the applicable period shall constitute an election on the part of NantWorks not to purchase all of the
shares of Common Stock which may be so transferred. 
 4.3.3 Within thirty (30) days after the conclusion of the applicable thirty
(30) day period referred to in Section 4.3.2, if an affirmative election has been made, NantWorks shall purchase, and the Restricted Selling Holder who gave the original notice shall sell, such shares of Common Stock subject to the
election upon the price and terms of payment designated in such notice. If the notice provides for the payment of non-cash consideration, NantWorks may elect to pay the consideration in cash equal to either (i) the fair market value as
determined by the Board and the Restricted Selling Holder or (ii) the determination of the present fair market value of the non-cash consideration offered, as determined by an independent third-party appraiser appointed by mutual agreement of
the Board and the Restricted Selling Holder. 
 4.3.4 If NantWorks elects not to purchase all of the shares of Common Stock designated in
such notice, then the Restricted Selling Holder may transfer to the proposed transferee all of the shares of Common Stock described in the such notice, provided that such transfer (i) is completed within one-hundred and twenty (120)
days after the expiration of NantWorks’ right of first refusal on such shares of Common Stock (or, if applicable, within ten (10) days after receipt of the last of all required regulatory approvals), and (ii) is made on terms not less
favorable to the Restricted Selling Holder in the aggregate than as designated in the notice to Company and NantWorks. If such shares of Common Stock are not so transferred in accordance with the foregoing, the Restricted Selling Holder must give
notice in accordance with this section prior to any other or subsequent transfer of such shares of Common Stock. 

  
 - 15 - 

 4.4 Tag Along Rights. If NantWorks and/or any of its Affiliates (other than the Company)
or Permitted Transferees (an “Initiating Holder”) proposes to sell any shares of Common Stock to an unaffiliated third party (a “Tag Along Sale”), then the Initiating Holder shall deliver a notice (a “Tag Along
Sale Notice”) to Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and each of the 3BE Members stating that the Initiating Holder proposes to effect a Tag Along Sale and providing the terms of the Tag Along Sale, and
Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and each of the 3BE Members may each elect, by written notice to such Initiating Holder given within fifteen (15) days from the date of the Tag Along Sale Notice, to sell on
the same terms and conditions (on a per share basis) as the sale by such Initiating Holder up to the same percentage (the percentage so elected by Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and each of the 3BE Members is
herein referred to as the “Elected Percentage”) of Verizon’s shares of Common Stock, Celgene’s shares of Common Stock, BlackBerry’s shares of Common Stock, NHealth’s shares of Common Stock, KHealth’s shares
of Common Stock, Blackstone’s shares of Common Stock, Allscripts’ shares of Common Stock and each of the 3BE Members’ shares of Common Stock, respectively, as the percentage of the Initiating Holder’s Common Stock that such
Initiating Holder proposes to sell. If Verizon, Celgene, BlackBerry NHealth, KHealth, Blackstone, Allscripts and/or any of the 3BE Members elects to sell the Elected Percentage of its Common Stock pursuant to this Section 4.4, then the
Initiating Holder shall cause the proposed purchaser to purchase from Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts, and each of the 3BE Members as applicable, and Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone,
Allscripts and each of the 3BE Members shall sell to the proposed purchaser, simultaneously with the sale by such Initiating Holder and on substantially the same terms and conditions (on a per share basis) as the sale by such Initiating Holder, the
Elected Percentage of Verizon’s Common Stock, the Elected Percentage of Celgene’s Common Stock, the Elected Percentage of BlackBerry’s Common Stock, the Elected Percentage of NHealth’s Common Stock, the Elected Percentage of
KHealth’s Common Stock, the Elected Percentage of Blackstone’s Common Stock, the Elected Percentage of Allscripts’ Common Stock and the Elected Percentage of the 3BE Members’ Common Stock; provided, that in connection with any
Tag-Along Sale, (x) neither Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts or any of the 3BE Members shall be required to agree to any non-competition covenant or other agreement restricting the business operations of
Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts or the 3BE Members or their respective Affiliates, (y) neither Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts nor the 3BE Members shall be required
to make or become liable in respect of any representations and warranties relating to the Company or specifically to any Holder other than their self; and (z) any indemnification provided by Verizon, Celgene, BlackBerry, NHealth, KHealth,
Blackstone, Allscripts or any of the 3BE Members (other than with respect to the representations regarding their self-referenced in the foregoing clause (y)) shall not exceed and shall be based on, the relative purchase price being received by the
Initiating Holder, Verizon, Celgene, BlackBerry, NHealth, KHealth, Blackstone, Allscripts and the 3BE Members, respectively, in the Tag-Along Sale, on a several, not joint, basis, or solely with recourse to an escrow established for the benefit of
the proposed purchaser (the Initiating Holder’s, Verizon’s, Celgene’s, BlackBerry’s, NHealth’s, KHealth’s, Blackstone’s, Allscripts’ and the 3BE Members’ contribution to such escrow to be on a pro rata
basis in accordance with the proceeds received from such Tag-Along Sale). The proceeds from the Tag Along Sale shall be distributed to the Initiating Holder and if participating in the Tag-Along Sale, Verizon, Celgene, BlackBerry, NHealth, KHealth,
Blackstone, Allscripts, and the 3BE Members pro rata based on the number of shares of Common Stock sold by them in the Tag Along Sale. 

  
 - 16 - 

 4.5 Drag Along Rights. 

4.5.1 If NantWorks and/or any other Holders (the “Selling Parties”) propose to sell a majority of the outstanding shares of
Common Stock of the Company to an unaffiliated third party (the “Drag Along Sale”), then the Selling Parties shall have the right, by written notice to each of the other Holders (the “Drag Along Holders”) given at
least fifteen (15) days prior to the Drag Along Sale and setting out the terms of the Drag Along Sale, to require that each Drag Along Holder sell the same percentage of each Drag-Along Holders’ shares of Common Stock as are sold by the
Selling Parties, with such sale to be on the same terms and conditions (other than the purchase price payable on a per share basis) relating to the sale of the Selling Parties’ shares of Common Stock; provided, however, that the
Selling Parties shall only have the rights set forth in this Section 4.5 with respect to a Drag Along Sale in which (a) each Drag Along Holder receives in the transaction the same form of consideration, in the same proportion (on the basis
of the consideration to be received in such Drag Along Sale) as the Selling Parties and (b) the Drag-Along Holders receive such Drag-Along Holder’s pro rata share of the consideration paid (or proposed to be paid) by the transferee in such
Drag-Along Sale. For purposes of this Section 4.5.1, each Holder’s “pro rata share” shall be calculated based on the relative amount each Holder would be entitled to receive assuming the only outstanding shares of Common
Stock are those being sold (or proposed to be sold) by the Selling Parties and the Drag Along Holders in the Drag-Along Sale. 
 4.5.2 If
the Drag Along Sale is structured as a merger, consolidation or similar business combination, each Drag Along Holder will, if Holder approval of the transaction is required, vote in favor of the transaction. Each Drag Along Holder will take all
necessary or reasonably appropriate, advisable or desirable actions and will execute and deliver all necessary or reasonably appropriate, advisable or desirable documents, in each case in connection with the Drag Along Sale as requested by the
Selling Parties provided, that in connection with any Drag-Along Sale, (a) no Drag Along Holder shall be required to agree to any non-competition covenant or other agreement restricting the business operations of such Drag Along Holder
or its Affiliates, (b) no Drag Along Holder shall be required to make or become liable for any representations and warranties relating to the Company or specifically to any Holder other than their self; (c) neither the execution and
delivery of documents to be entered into in connection with the transaction, nor the performance of the Drag-Along Holder’s obligations thereunder, will cause a breach or violation of the terms of any law, judgment, order or decree of any court
or governmental agency applicable to such Drag-Along Holder or any agreement that would have a material adverse effect on such Drag-Along Holder; and (d) any indemnification provided by a Drag Along Holder shall not exceed and shall be based
on, the relative purchase price being received by the Selling Parties and Drag Along Holders in the Drag-Along Sale, on a several, not joint, basis, or with recourse solely to an escrow established for the benefit of the proposed purchaser (the
Selling Parties’ and Drag Along Holders’ contribution to such escrow to be on a pro rata basis in accordance with the proceeds received from such Drag-Along Sale). 

4.6 Merger and Consolidation. 

4.6.1 Subject to Sections 3.2 and 3.7, (i) any merger or consolidation of the Company with or into any other Person who is an Affiliate of
the Company shall require the vote or written consent of Holders holding shares of Common Stock representing (A) a majority of the shares of Common Stock that were issued at the time of the Conversion to the Former Series B Members, voting as a
separate class (the “Former Series B Class Vote”), (B) a majority of the shares of Common Stock that were issued at the time of the Conversion to the Former Series E Members, voting as a separate class (the “Former
Series E Class Vote”), (C) a majority of the shares of Common Stock that were issued at the time of the Conversion to the Former Series F Members, voting as a separate class (the “Former Series F Class
Vote”), 

  
 - 17 - 

 
and (D) a majority of the shares of Common Stock that were issued at the time of the Conversion to the Former Series G Members, voting as a separate class (the “Former Series G
Class Vote”); and (ii) any merger or consolidation of the Company with or into any other Person who is not an Affiliate of the Company or any conversion of the Company into another entity in connection with any such merger or
consolidation, shall require only consent of Holders holding a majority-in-interest of the outstanding Common Stock, and no Former Series B Class Vote, Former Series E Class Vote, Former Series F Class Vote or Former Series G Class Vote. 

4.7 BlackBerry, NHealth, KHealth and Allscripts Rights. 

4.7.1 If any Person purchases shares of Common Stock or Preferred Stock such that the purchase price per share paid by such Person for such
Common Stock or Preferred Stock is equal to or less than the purchase price paid per unit by BlackBerry for the Series D Units, and such Person receives (or has received) any rights, preferences, privileges or other benefits in respect of its
Common Stock or Preferred Stock that BlackBerry does not enjoy in respect of its Common Stock, then BlackBerry shall automatically, without any further action of the Board or any Holder, be entitled to such rights, preferences, privileges or
benefits in respect of its Common Stock. For the avoidance of doubt, this Section 4.7.1 shall not apply if any Person purchases any other class or series of capital stock of the Company or if any Person purchases shares of Common Stock or
Preferred Stock such that the purchase price per share paid by such Person for its Common Stock or Preferred Stock is more than the purchase price per unit paid by BlackBerry for its Series D Units. 

4.7.2 If any Person purchases shares of Common Stock or Preferred Stock such that the purchase price per share paid by such Person for such
Common Stock or Preferred Stock is equal to or less than the purchase price per unit paid by NHealth for its Series E Units, and such Person receives (or has received) any rights, preferences, privileges or other benefits in respect of its
Common Stock or Preferred Stock that NHealth does not enjoy in respect of its Common Stock, then NHealth shall automatically, without any further action of the Board or any Holder, be entitled to such rights, preferences, privileges or benefits in
respect of its Common Stock. For the avoidance of doubt, this Section 4.7.2 shall not apply if any Person purchases any other class or series of capital stock of the Company or if any Person purchases shares of Common Stock or Preferred Stock
such that the purchase price per share paid by such Person for its Common Stock or Preferred Stock is more than the purchase price per unit paid by NHealth for its Series E Units. 

4.7.3 If any Person purchases shares of Common Stock or Preferred Stock such that the purchase price per share paid by such Person for such
Common Stock or Preferred Stock is equal to or less than the purchase price per unit paid by KHealth for its Series F Units, and such Person receives (or has received) any rights, preferences, privileges or other benefits in respect of its
Common Stock or Preferred Stock that KHealth does not enjoy in respect of its Common Stock, then KHealth shall automatically, without any further action of the Board or any Holder, be entitled to such rights, preferences, privileges or benefits in
respect of its Common Stock. For the avoidance of doubt, this Section 4.7.3 shall not apply if any Person purchases any other class or series of capital stock of the Company or if any Person purchases Common Stock or Preferred Stock such that
the purchase price per share paid by such Person for its Common Stock or Preferred Stock is more than the purchase price per unit paid by KHealth for its Series F Units. 

4.7.4 If any Person purchases shares of Common Stock or Preferred Stock such that the purchase price paid per share by such Person for such
Common Stock or Preferred Stock is equal to or less than the purchase price per unit paid by Allscripts for its Series G Units, and such Person receives (or has received) any rights, preferences, privileges or other benefits in respect of its
Common Stock or 

  
 - 18 - 

 
Preferred Stock that Allscripts does not enjoy in respect of its Common Stock, then Allscripts shall automatically, without any further action of the Board or any Holder, be entitled to such
rights, preferences, privileges or benefits in respect of its Common Stock. For the avoidance of doubt, this Section 4.7.4 shall not apply if any Person purchases any other class or series of capital stock of the Company or if any Person
purchases Common Stock or Preferred Stock such that the purchase price per share paid by such Person for its Common Stock or Preferred Stock is more than the purchase price per unit paid by Allscripts for its Series G Units. 

ARTICLE 5 
 RECORDS

 5.1 Books and Records. The books and records of the Company shall be kept, and the financial position and the results of its
operations recorded, in accordance with the accounting methods followed for federal income tax purposes. The books and records of the Company shall reflect all Company transactions and shall be appropriate and adequate for the Company’s
business. 
 5.2 Financial Information. The Company shall deliver to Verizon, Celgene, BlackBerry, NHealth, KHealth, Allscripts and
each of the 3BE Members, for so long as each of them or Celgene’s Affiliates, BlackBerry’s Affiliates, NHealth’s Affiliates, KHealth’s Affiliates, Allscripts’ Affiliates, or any of the 3BE Members’ Affiliates,
respectively, owns any shares of Common Stock (unless Verizon, Celgene, BlackBerry, NHealth, KHealth, Allscripts or any of the 3BE Members at any time specifically requests that such information not be delivered to it): 

5.2.1 as soon as available, but in any event within one hundred twenty (120) days after the end of each Fiscal Year, a consolidated
income statement and statement of cash flows for, and a consolidated balance sheet as of the last day of, such Fiscal Year, prepared in all material respects in accordance with generally accepted accounting principles in the United States; 

5.2.2 as soon as available, but in any event within sixty (60) days after the end of each of the first three fiscal quarters of each
Fiscal Year, an unaudited consolidated income statement and statement of cash flows for, and an unaudited consolidated balance sheet as of the last day of, such quarter, prepared in all material respects in accordance with generally accepted
accounting principles in the United States, except for the absence of notes that may be required by generally accepted accounting principles in the United States and as otherwise indicated in the financial statements; and 

5.2.3 within thirty (30) days prior to the beginning of each Fiscal Year, a copy of the Company’s annual operating budget. 

5.3 Inspection of Records. 

5.3.1(a) Each Holder that holds Common Stock representing on a fully-diluted basis at least three percent (3%) of the total outstanding
shares of Common Stock, (b) Celgene, so long as it holds the Minimum Celgene Ownership Amount, (c) BlackBerry, so long as it holds the Minimum BlackBerry Ownership Amount, (d) NHealth, so long as it holds the Minimum NHealth Ownership
Amount, (e) KHealth, so long as it holds the Minimum KHealth Ownership Amount, (f) Blackstone, so long as it holds the Minimum Blackstone Ownership Amount, (f) Allscripts, so long as it holds the Minimum Allscripts Ownership Amount
and (g) each of the 3BE Members, so long as they, on a combined basis, hold the Minimum 3BE Members’ Ownership Amount, shall have the right, at reasonable times, to inspect and copy during normal business hours any of the Company’s
records, including the Company Charter and any amendment thereto, this Agreement, minutes of the meetings of the Board and the 

  
 - 19 - 

 
Holders, the Company’s federal, state, and local income tax or information returns for each Fiscal Year, and all financial statements prepared with respect to the Company and its operations.
Any request, inspection or copying by a Holder under this Section 5.3 may be made by that Holder or that Holder’s agent or attorney. Notwithstanding the foregoing, the Company shall not be obligated pursuant to this Section 5.3 to
provide access to any information that is not financial information and that the Company reasonably considers to be a trade secret or similar sensitive competitive information; and provided further that the requesting Holder and its
designated representatives shall, if requested by the Company, execute a confidentiality and nondisclosure agreement in customary form prior to any such inspection. 

5.3.2 Subject to compliance with any privacy and confidentiality restrictions imposed by law, including HIPAA, and subject to the execution of
appropriate confidentiality, business associate and other agreements, Celgene shall be provided access to the Company’s health data base and related information. The Company will provide Celgene such access through physical or electronic means,
subject to reasonable requirements that the Company may impose and upon which the parties mutually agree, including with respect to physical access, time and place restrictions and with respect to electronic access, security and compatibility
requirements. 
 5.4 Confidentiality. 

5.4.1 The Holders hereby acknowledge that the Company will be in possession of confidential information the improper use or disclosure of which
could have a material adverse effect upon the Company, or one or more Holders. 
 5.4.2 The Holders acknowledge and agree that all
information provided to them by or on behalf of the Company concerning the business or assets of the Company that is identified as confidential at the time of disclosure shall not, without the prior written consent of the Board, be disclosed to any
Person (other than a Holder). Notwithstanding the previous sentence, each Holder may disclose Company confidential information to such Holder’s accountants, attorneys and similar advisors bound by a duty of confidentiality and to a proposed
transferee bound by a confidentiality agreement, the form of which has been provided to the Board; moreover, the foregoing requirements of this Section 5.4 shall not apply to a Holder with regard to any information that is currently or becomes:
(i) required to be disclosed pursuant to applicable law or a domestic national securities exchange rule (but in each case only to the extent of such requirement); (ii) required to be disclosed in order to protect such Holder’s
interest in the Company or in any dispute between or among the Holders; (iii) publicly known or available in the absence of any improper or unlawful action on the part of such Holder or (iv) known or available to such Holder other than
through or on behalf of the Company, it being understood that information about the services provided by a Holder to the Company shall not be deemed as becoming known or available through or on behalf of the Company. Notwithstanding anything to the
contrary in this Agreement, a Holder may use any Residual Information for any purpose; provided that such learning, skills, ideas, concepts, techniques, know-how, and information was not intentionally memorized for the purpose of retaining
and subsequently using them outside of the purposes contemplated by this Agreement. 
 5.5 Intellectual Property Rights. In the event
the Company is dissolved or wound up, the Company shall and shall cause each of its wholly-owned subsidiaries to, and the Company shall use reasonable best efforts to cause each other subsidiary of the Company that is an Affiliate to, grant to
Verizon, Celgene, BlackBerry, NHealth, KHealth and Allscripts a royalty-free, fully paid-up, non-exclusive, perpetual license to use, sell or license (i) all owned patents, patent applications and trade secrets or similar intellectual property
rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, and licenses in, to and under any of the foregoing, in each case to the extent the applicable subsidiary is not prohibited from doing so, and (ii) any
of the foregoing that are 

  
 - 20 - 

 
licensed to the Company or each controlled subsidiary that is an Affiliate and that are not prohibited from being sublicensed, in each case that Verizon, Celgene, BlackBerry, NHealth, KHealth and
Allscripts or any of their respective Affiliates then uses, sells or licenses (or then has definitive plans to do so) in the manner in which Verizon, Celgene, BlackBerry, NHealth, KHealth or Allscripts or their respective Affiliates then uses, sells
or licenses (or then has definitive plans to use, sell or license) such intellectual property. 
 ARTICLE 6 

MISCELLANEOUS 
 6.1
Termination. This Agreement shall terminate (and be of no further force or effect) immediately prior to the earliest to occur of a Qualified IPO and a Liquidity Event, except for Article 1, Section 3.8, Section 5.4,
Section 5.5 and Article 6 (other than Sections 6.8 and 6.11), which shall continue in full force and effect. 
 6.2 Binding
Effect. Subject to the provisions of this Agreement relating to transferability, this Agreement will be binding upon and inure to the benefit of the Holders, and their respective successors and assigns. 

6.3 Headings. All headings herein are inserted only for convenience and ease of reference and are not to be considered in the
construction or interpretation of any provision of this Agreement. 
 6.4 References to this Agreement. Numbered or lettered
articles, sections and subsections herein contained refer to articles, sections and subsections of this Agreement unless otherwise expressly stated. 

6.5 Pronouns; Statutory References. All pronouns and all variations thereof shall be deemed to refer to the masculine, feminine, or
neuter, singular or plural, as the context in which they are used may require. 
 6.6 Interpretation. In the event any claim is made
by any Holder relating to any conflict, omission or ambiguity in this Agreement, no presumption or burden of proof or persuasion shall be implied by virtue of the fact that this Agreement was prepared by or at the request of a particular Holder or
his or her counsel. Whenever a provision in this Agreement authorizes or permits the Board to act in “its discretion” or “sole discretion,” such provision shall mean that the decision to take applicable action (or decline or
refuse to take such action) shall be in the sole and absolute discretion of the Board, who may consider (or decline to consider) any factors as it determines. 

6.7 Governing Law. The Holders expressly agree that all the terms and provisions hereof shall be construed under the laws of the State
of Delaware, without regard to conflicts of laws principles. 
 6.8 Dispute Resolution. 

6.8.1 In an effort to informally and amicably resolve any claim, controversy or dispute arising out of or relating to this Agreement or the
breach thereof, and regardless whether such claim sounds in contract, tort, or otherwise (a “Dispute”), each Holder shall provide written notice to the other Holders with which it has a Dispute that requires resolution. Such notice
shall set forth the nature of the Dispute, the amount, if any, involved and the remedy sought. Each Holder involved in the Dispute shall designate a representative who shall be empowered to investigate, discuss and seek to settle or otherwise
resolve the Dispute. If the representatives are unable to resolve the Dispute within thirty (30) days after 

  
 - 21 - 

 
proper notification, the Dispute shall be submitted to the most senior executive of each Holder involved in the Dispute (or (x) in the case of Celgene, to an officer of Celgene designated by
Celgene, and (y) in the case of BlackBerry, to an officer designated by BlackBerry) for consideration for an additional thirty (30) days. 

6.8.2 Each of the Holders: (i) hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts in the State of
Delaware (the “Chosen Courts”) for the purposes of any Dispute; (ii) hereby waives, to the extent not prohibited by applicable law, and agrees not to assert by way of motion, as a defense or otherwise, in any such Dispute, any
claim that it or he is not subject personally to the jurisdiction of the Chosen Courts, that its property is exempt or immune from attachment or execution, that any such proceeding brought in the Chosen Courts is improper or that this Agreement or
the subject matter hereof may not be enforced in or by such court; and (iii) hereby agrees not to commence any Dispute other than before the Chosen Courts nor to make any motion or take any other action seeking or intending to cause the
transfer or removal of any such claim or action to any court other than the Chosen Courts whether on the grounds of inconvenient forum or otherwise. Each of the parties hereto hereby consents to service of process in any such proceeding, and agree
that service of process by registered or certified mail, return receipt requested, at its address specified pursuant to Section 6.12 is reasonably calculated to give actual notice. 

6.8.3 TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH PARTY HERETO HEREBY WAIVES AND COVENANTS THAT IT WILL NOT
ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE OR ACTION, CLAIM, CAUSE OF ACTION OR SUIT (IN CONTRACT, TORT OR OTHERWISE), INQUIRY, PROCEEDING OR INVESTIGATION ARISING OUT OF OR
BASED UPON THIS AGREEMENT OR THE SUBJECT MATTER HEREOF OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING. EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS
BEEN INFORMED BY THE OTHER PARTIES HERETO THAT THIS SECTION 6.8.3 CONSTITUTES A MATERIAL INDUCEMENT UPON WHICH THEY ARE RELYING AND WILL RELY IN ENTERING INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY. ANY PARTY HERETO MAY FILE AN
ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 6.8.3) WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

6.8.4 In addition, each Holder may seek equitable relief in the Chosen Courts if any provision of this Agreement is not performed in
accordance with its terms and for which such Party would not have an adequate remedy for money damages. Any such remedy will be in addition to any other remedy that may be available at law. Without limiting the generality of the foregoing, the
parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, the parties agree that, in addition to
any other remedies, each party shall be entitled to enforce the terms of this Agreement by a decree of specific performance without the necessity of proving the inadequacy of money damages as a remedy and without regard to anything to the contrary
contained in applicable law. Each party hereby waives any requirement for the securing or posting of any bond in connection with such remedy. Each party further agrees that the only permitted objection that it may raise in response to any action for
equitable relief is that it contests the existence of a breach or threatened breach of this Agreement. 

  
 - 22 - 

 6.9 Schedules, Appendices and Exhibits. All Schedules and Appendices attached to this
Agreement are incorporated and shall be treated as if set forth herein. 
 6.10 Severability. If any provision of this Agreement or
the application of such provision to any person or circumstance shall be held invalid, the remainder of this Agreement or the application of such provision to persons or circumstances other than those to which it is held invalid shall not be
affected thereby. 
 6.11 Additional Documents and Acts. Each Holder agrees to execute and deliver such additional documents and
instruments and to perform such additional acts as may be necessary or appropriate to effectuate, carry out and perform all of the terms, provisions, and conditions of this Agreement and the transactions contemplated hereby. 

6.12 Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this
Agreement shall be in writing and shall be conclusively deemed to have been duly given when sent to a Holder to the address or facsimile number set forth on Schedule A hereto: (a) when hand delivered to the Holder; (b) when
sent by facsimile if sent between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day, or on the next business day if sent other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day;
(c) three business days after deposit in the U.S. or overseas mail with first class or certified mail receipt requested postage; or (d) the next business day after deposit with a national overnight delivery service, postage prepaid, with
next business day delivery guaranteed, provided that the sending party receives a confirmation of delivery from the delivery service provider. A Holder may change or supplement the addresses given on Schedule A, or designate
additional addresses, for purposes of this Section 6.12 by giving written notice of the new address to the Board. 
 6.13
Amendments. Except as otherwise provided in this Agreement, this Agreement may be amended only with the written consent of the Board and by consent of Holders holding a majority-in-interest of the outstanding Common Stock; provided,
that Article 2, Article 3, Article 4, Section 5.2, Section 5.3, Section 5.4, Section 5.5, Section 6.1, this Section 6.13, and Appendix 1 may not be amended in any manner adversely affecting the rights or
obligations of Verizon or Celgene or Celgene’s Affiliates or BlackBerry or BlackBerry’s Affiliates or NHealth or NHealth’s Affiliates or KHealth or KHealth’s Affiliates, Allscripts or Allscripts’ Affiliates or each of 3BE
Members or 3BE Members’ Affiliates, respectively under this Agreement in any material respect without Verizon’s, Celgene’s, BlackBerry’s, NHealth’s, KHealth’s, Allscripts’ or each such 3BE Members’ respective
prior written consent (it being understood that the creation and issuance of a series of equity securities with rights, preferences or privileges senior to, or pari passu with, the Common Stock shall not be deemed to require the consent of Verizon,
Celgene, BlackBerry, NHealth, KHealth, Allscripts or any 3BE Member under this Section 6.13 solely as a result of such security having rights, preferences or privileges senior to, or pari passu with, the Common Stock); provided,
further, that no other provision of this Agreement may be amended in a manner that adversely and disproportionately affects the rights or obligations of any Holder under this Agreement in any respect without the prior written consent of such
Holder. Notwithstanding anything to the contrary in this Agreement (including this Section 6.13), each Holder who is not party to this Agreement as of its original date shall automatically become party hereto upon the execution and delivery of
a counterpart signature page or joinder hereto, and such execution and delivery shall not require the consent of any other party hereto and shall not be deemed to be an amendment or modification to this Agreement. In the event that Verizon is no
longer a Holder or otherwise no longer holds its approval rights set forth in Sections 2.1.5, 2.1.6(f) and 3.2 and in the event Celgene continues to hold the Minimum Series B Ownership Amount, Celgene shall automatically assume Verizon’s rights
pursuant to such Sections (it being understood and agreed that Celgene shall thereafter hold such rights subject to any 

  
 - 23 - 

 
required holdings, i.e., Minimum Series B Ownership Amount). In the event neither Celgene or Verizon hold the approval rights set forth in Sections 2.1.5, 2.1.6(f), 3.2 and 3.4, and in the event
BlackBerry continues to hold the Minimum Series D Ownership Amount, BlackBerry shall automatically assume the rights pursuant to such Sections (it being understood and agreed that BlackBerry shall thereafter hold such rights subject to any required
holdings, i.e., Minimum Series D Ownership Amount). 
 6.14 Reliance on Authority of Person Signing Agreement. If a Holder is not a
natural person, neither the Company nor any Holder will be required to determine the authority of the individual signing this Agreement to make any commitment or undertaking on behalf of such entity or to determine any fact or circumstance bearing
upon the existence of the authority of such individual. 
 6.15 Multiple Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 
 6.16 Remedies
Cumulative. The remedies under this Agreement are cumulative and shall not exclude any other remedies to which any person may be lawfully entitled. 

[Remainder of Page Left Intentionally Blank] 

  
 - 24 - 

 IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written. 

 

			
	NANTWORKS, LLC
		
	By:	 	  

	Name:	 	
	Title:	 	

 SCHEDULE A 

STOCKHOLDERS 

[    ] 

  
 Appendix 1 - 1 

 APPENDIX 1 

Definitions 
 As used in
the foregoing Agreement, the following terms shall have the meanings set forth below: 
 “Affiliate” means, with respect to
any Person, any other Person, directly or indirectly, through one or more intermediaries, controlling, controlled by, or under common control with such Person. The term “control,” as used in the immediately preceding sentence means, with
respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of the controlled Person. For a Person that is an individual, the term Affiliate shall include such
individual’s ancestors, siblings, descendants and spouses of any of the foregoing. For the avoidance of doubt, Patrick Soon-Shiong and his Affiliates shall be deemed to be Affiliates of the Company and of NantWorks. 

“BlackBerry Competitor” means each of Apple Inc. and Samsung Electronics Co. Ltd., and any of their subsidiaries or
Affiliates. 
 “Common Stock” means shares of common stock, par value $0.001, of the Company. 

“Company Charter” means the certificate of incorporation of the Company, as amended and supplemented from time to time. 

“Convertible Securities” means options to purchase or rights to subscribe for shares of Common Stock or securities by their
terms convertible into or exchangeable for shares of Common Stock. 
 “Damages” means any and all losses, damages, expenses
and liabilities whether joint or several, including, without limitation, those losses, damages, expenses and liabilities (including reasonable attorneys’ fees) arising under or connected with the securities laws of the United States, or any
other provision of statutory law, common law, or other applicable law of any jurisdiction. 
 “Fiscal Year” means the
Company’s fiscal year, which shall commence on January 1 and end on December 31 of each year. 
 “Former Series A
Members” means the holders of Series A units of Nant Health, LLC immediately prior to the Conversion. 
 “Former Series B
Members” means Verizon and Celgene. 
 “Former Series D Member” means Blackberry. 

“Former Series E Member” means NHealth. 

“Former Series F Member” means KHealth. 

“Indemnifiable Person” means (i) each Director, (ii) any officer, employee, attorney, agent, or representative of
the Company, and (iii) each Holder. 

  
 Appendix 1 - 1 

 “Liquidity Event” means, the consummation of (a) any reorganization,
merger, consolidation or other transaction or series of related transactions in which the Holders as constituted immediately prior to such transaction or series of related transactions will, immediately after such transaction or series of related
transactions (by virtue of securities issued in such transaction or series of related transactions) fail to hold at least 50% of the voting power of the resulting or surviving entity or its parent company following such transaction or series of
related transactions; or (b) a sale, lease, transfer or license of all or substantially all of the assets of the Company (taken together as a whole with its subsidiaries), or a related series of transactions that, taken together (including,
without limitation, a liquidation, dissolution or other winding up of the Company), result in the sale or other disposition of all or substantially all of the assets of the Company (taken together as a whole with its subsidiaries); provided,
that the issuance of Common Stock or other securities pursuant to customary venture capital financings by the Company where pre-emptive rights have been made available to the Preemptive Rights Holders pursuant to Section 2.2 shall not be deemed
a Liquidity Event. 
 “Minimum 3BE Members’ Ownership Amount” means such number of Common Stock equal to a majority of
the shares of Common Stock that were issued at the time of the Conversion to the 3BE Members; provided that any calculation of the 3BE Members’ ownership shall include the 3BE Members and their Permitted Transferees who are Affiliates of
the 3BE Members. 
 “Minimum Allscripts Ownership Amount” means such number of Common Stock equal to a majority of the
shares of Common Stock that were issued at the time of the Conversion to Allscripts; provided that any calculation of Allscripts’ ownership shall include Allscripts and its Permitted Transferees who are Affiliates of Allscripts. 

“Minimum Blackberry Ownership Amount” means such number of Common Stock equal to a majority of the shares of Common Stock
that were issued at the time of the Conversion to Blackberry; provided that any calculation of BlackBerry’s ownership shall include BlackBerry and its Permitted Transferees who are Affiliates of BlackBerry. 

“Minimum Blackstone Ownership Amount” means such number of Common Stock equal to a majority of the shares of Common Stock
that were issued at the time of the Conversion to Blackstone; provided that any calculation of Blackstone’s ownership shall include Blackstone and its Permitted Transferees who are Affiliates of Blackstone. 

“Minimum Celgene Ownership Amount” means such number of Common Stock equal to a majority of the shares of Common Stock that
were issued at the time of the Conversion to Celgene; provided that any calculation of Celgene’s ownership shall include Celgene and its Permitted Transferees who are Affiliates of Celgene. 

“Minimum NHealth Ownership Amount” means such number of Common Stock equal to a majority of the shares of Common Stock that
were issued at the time of the Conversion to NHealth; provided that any calculation of NHealth’s ownership shall include NHealth and its Permitted Transferees who are Affiliates of NHealth. 

“Minimum KHealth Ownership Amount” means such number of Common Stock equal to a majority of the shares of Common Stock that
were issued at the time of the Conversion to KHealth; provided that any calculation of KHealth’s ownership shall include KHealth and its Permitted Transferees who are Affiliates of KHealth. 

  
 Appendix 1 - 2 

 “Minimum Verizon Ownership Amount” means such number of Common Stock equal to a
majority of the shares of Common Stock that were issued at the time of the Conversion to Verizon; provided that any calculation of Verizon’s ownership shall include Verizon and its Permitted Transferees who are Affiliates of Verizon,

 “Nant Health Business” means the development and commercialization of clinical, analytical and supportive services and
products that facilitate managing care delivery to reduce costs and improve patient outcomes or support coordinated care delivery, population health management, clinical decision support, predictive modeling, evidence based/precise medicine,
intelligent clinical monitoring or data aggregation, and other products and services incidental to the foregoing. 
 “Permitted
Transferee” shall mean, with respect to any Holder, (i) an Affiliate of such Holder, (ii) a bona fide third party purchaser of the Common Stock pursuant to a Liquidity Event, (iii) any Person that directly or indirectly
acquires all or substantially all of the ownership interests or assets of such Holder, (iv) any liquidating trust established in connection with the liquidation, dissolution and winding up of such Holder for purposes of holding the assets of
such Holder for the benefit of the former partners, members or equity holders thereof, (v) such Holder’s spouse (provided that in any community property state, each spouse agrees in writing to be bound by the terms of this
Agreement), (vi) any descendants (whether natural or adopted) of such Holder or of Holder’s spouse, (vii) any trust or other entity formed for estate planning purposes for the benefit of such Holder or a Person specified in
(v) or (vi) above or (viii) the Company, to the extent that it directly or indirectly acquires any shares of Common Stock held by KHealth, provided that such Permitted Transferee agrees in writing to be bound by the terms of
this Agreement. 
 “Person” means any natural person, corporation, membership, trust, partnership, limited liability
company, association or other entity. 
 “Qualified IPO” means the consummation of the first firm commitment underwritten
public offering of securities of the Company (or a corporate or other successor to the Company) pursuant to an effective registration statement under the Securities Act of 1933 (other than a registration statement relating either to the sale of
securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction) on a nationally recognized stock exchange with net proceeds to the Company of not less than $75.0 million (before
deduction of underwriters’ fees, commissions and expenses). 

  
 Appendix 1 - 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]